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It is recognized that there exist reservoirs of HIV located outside the bloodstream, and
that these reservoirs hinder the efficacy of antiretroviral medication regimens in combating
the virus. The prevailing theories regarding these reservoirs point to the lymphatic system.
In this work, we discuss a novel computational model of viral dynamics in the lymph node,
to allow numerical studies of viral “reservoirs” causing reinfection. Our model consists of a
system of advection-reaction-diffusion partial differential equations (PDEs), where the diffu-
sion coefficients vary between species (virus, drugs, lymphocytes) and include discontinuous
jumps to capture differing properties of internal lymph node structures. We present the
mathematical model and discuss our current work on implementing this using the MFEM
finite-element infrastructure. Using this model, we analyze the clinical course of HIV in-
fection and the effects of different combinations of anti-retroviral drugs, and then use this
model to test the hypothesis whether the lymph node can serve as a reservoir of HIV.
v
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The first cases of the acquired immune deficiency syndrome (AIDS) were found
in 1981 in Los Angeles among five young men, but it is believed that cases of the disease
had been occurring unrecognized for several years before its identification. As it seemed
to be spread by contact with body fluids, it was early suspected to be caused by a new
virus, and by 1983 the agent now known to be responsible for AIDS, called the human
immunodeficiency virus (HIV), was isolated and identified.
HIV infection does not immediately cause AIDS. It may take more than ten years for HIV
infected patients to progress to positive disease. Nowadays, HIV is a worldwide pandemic
and, although great progress has been made to understand the pathogenesis and epidemi-
ology of the disease, the number of infected people around the world continues to grow at
an alarming rate, presaging the death of many people from AIDS for many years to come.
Estimates from the World Health Organization are that 16.3 million people have died from
AIDS since the beginning of the epidemic [36].
Figure 1.1. Adult HIV prevalence [image source: KFF org.]
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With the advent of powerful anti-HIV drugs developed in the 1990’s, the inevitability of
getting AIDS after being diagnosed with HIV has drastically changed. In fact, antiretroviral
therapy (ART) changed HIV from a terminal into a chronic disease. Unfortunately, the
medical community was a bit overly optimistic; when the viral load became undetectable,
patients would be removed from drug therapy and the virus would rebound [22]. Now it
is recognized that there are reservoirs of HIV located outside the bloodstream. With the
notable exception of a famous patient in Berlin, Germany, all HIV positive patients taken
off drug therapy (when the viral level appears to have dropped to zero in the bloodstream)
have had a return of the virus, sometimes within only a few weeks. It is therefore an urgent
requirement to locate these reservoirs, understand the mechanisms of how they are formed,
and find a new drug therapy to cure HIV completely [28].
There are several prevailing theories about why HIV has remained incurable so far [28].
First, the host cells for the virions are CD4 T helper cells, white blood cells essential to a
functioning immune system. Their main role is to signal other T-cells to destroy pathogens.
Once a CD4 T-cell becomes actively infected by HIV, the immune cell is usually destroyed;
although it can also happen that the HIV enters the cell and produces viral DNA but does
not complete the replication process. While drug therapies appear to inhibit the replication
of virtually all active susceptible virions in the blood, there seem to be virions hiding outside
the path of the drugs [28].
Although viral load and turnover are usually measured by detecting the viral RNA present
in viral particles in the blood, the majority of HIV infection happened in lymphoid tissue, in
which infected CD4 T-cells, monocytes, macrophages, and dendritic cells are found. More
than 95% of the virus that can be detected in the plasma is derived from productively
infected cells, which have a very short half-life. Productively infected CD4 lymphocytes are
found in the T-cell areas of lymphoid tissue, and these are thought to succumb to infection
in the course of being activated in an immune response. Latently infected memory CD4 cells
that are activated in response to antigen presentation also produce virus. Such cells have a
longer half-life of 2 to 3 weeks from the time that they are infected. Once activated, HIV can
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spread from these cells by rounds of replication to other activated CD4 T-cells. In addition
to the cells that are infected productively or latently, there is a further large population of
cells infected by defective proviruses; although such cells are not a source of infectious virus
[36].
Secondly, virus continuously replicates in the lymph nodes, away from the bloodstream,
and when it hits the bloodstream it is destroyed by the ongoing drug regimen. However,
when drugs are stopped, the virus has no restrictions to its replication and the viral levels
soar again. This works since the blood circulates quickly, on a much faster time scale than
lymph.
Another theory is that some T-cells in the lymphatic system are harboring resting T-cells
that hold the viral DNA but are not producing more virus. Such type of non-productive
infected cells, also known as latent cells, carry the infection without triggering replication or
destroying the cells [21].
Although there exist numerous mathematical models in biology, there are very few math-
ematical models of the lymphatic system. While there do exist some basic models for the
entire lymphatic system, there are indeed very few highly accurate models for individual
elements of the lymphatic system such as the lymph node. Thus to analyze the functionality
of drug therapies, and how these enter and interact with HIV in the lymph node, we need
to first construct a high-fidelity mathematical model for these organs, which served as an
inspiration for this research.
For this work, we wish to derive a three-dimensional geometric model of the lymph
node. With this new model in hand, we will implement scalable parallel solver algorithms to
generate approximate solutions to these partial differential equations using continuous finite
element methods.
We have organized this thesis as follows. Chapter 2 introduces the basic biological con-
cepts, including the human immune response to HIV. We then present the framework of our
mathematical model response to the HIV (or Ebola) infection in the lymph node, as well as
our model for how relevant products are transported to and from the lymph node.
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In Chapter 3 we present the algorithmic details behind our solution process. In Chapter
4 we discuss our investigation of optimal preconditioners for accelerating convergence when
using the GMRES methods as an iterative linear solver. In Chapter 5 we present the nu-
merical preparation for solving the model, including the details of mesh generation and the
various tests we employed to verify each part of our model and solution process. With these
in place, we then proceed to the overall biological model in Chapter 6, where we analyze the
model with all known biological parameters included, and test our hypothesis regarding HIV
reservoir effects of the lymph node. Finally, in Chapter 7 we summarize the contributions




As shown in Figure 2.1, the human lymph node is an oval or bean-shaped organ of the
lymphatic system. It plays a critical role in the development of an appropriate and efficient
immune response. Lymph nodes are a type of peripheral or secondary lymphoid organ. They
are found in many locations throughout the body where lymphatic vessels converge, and are
sites where adaptive immune responses are initiated [36]. There are a variety of biological
and physical process that are involved in the immune reaction such as diffusion, chemotaxis,
receptor expression, etc. As soon as an Antigen (Ag) is captured by Ag-processing cells it is
transmitted to the nearest lymph node, where it is then presented to specific lymphocytes
to trigger an immune response [9].
Figure 2.1. The lymph node
In order to discuss the immune response, we must first define some basic terminology.
The first one is pathogens: a bacterium, virus, or other microorganism that can cause
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disease. Antigens are any substance foreign to the body that evokes an immune response
either alone or through forming a complex with a larger molecule and that is capable of
binding with a product of the immune response. Finally an antibody is any one of a large
number of proteins of high molecular weight that are produced normally by specialized B
cells after stimulation by an antigen, and that act specifically against the antigen in an
immune response [49].
In the body, the blood and the extracellular spaces are the only areas where pathogens
can be accessed by antibodies. However, some bacterial pathogens and all viruses replicate
inside cells where they cannot be detected by antibodies. The destruction of these invaders
is the function of the T lymphocytes, which are responsible for the cell-mediated immune
responses of adaptive immunity [36]. The T lymphocyte, or T-cell, is a type of lymphocyte
which arises from stem cells in bone marrow and differentiates in the thymus. T lymphocytes
migrate from these tissues and are carried in the bloodstream to the peripheral or secondary
lymphoid organs (e.g., the lymph nodes). There are two essential classes of T-cells, the T
helper cell (Th cell), also known as CD4 cells or suppressor T-cells, that take fine control of
the immune response through the secretion of cytokines, whereas the Cytotoxic T-cells kill
the foreign or intracellularly infected cells directly.
Cell-mediated reactions depend on direct interactions between T lymphocytes and cells
bearing the antigen that the T-cells recognize. The actions of cytotoxic T-cells are the
most direct. These recognize any of the body’s cells that are infected with viruses, which
replicate inside cells, using the biosynthetic machinery of the cell itself. The replicating virus
eventually kills the cell, releasing new virus particles. Antigens derived from the replicating
virus are, however, displayed on the surface of infected cells, where they are recognized by
cytotoxic T-cells. These cells can then control the infection by killing the infected cell before
viral replication is complete (Figure 2.2). Cytotoxic T-cells typically express the molecule
CD8 on their cell surfaces [36].
CD4 T lymphocytes, which carry out different functions in defending the body, in par-
ticular from bacterial infections, can be divided into two subsets. The first subset of CD4 T
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Figure 2.2. Mechanism of host defense against intracellular infection by viruses [36]
lymphocytes, known as a TH1 cells, is important in the control of intracellular bacterial in-
fections. TH1 cells will activate macrophages, inducing the fusion of their lysosomes with the
vesicles containing the bacteria and at the same time stimulating other antibacterial mech-
anisms of the phagocyte. In addition to killing infected cells and activating macrophages,
T-cells also have a central role in the destruction of extracellular pathogens by activating B
cells. This is the specialized role of the second subset of CD4 T-cells, called TH2 cells [36].
The human immunodeficiency virus (HIV) is an enveloped retrovirus, which inter-
acts with the immune system and that ultimately leads to loss of immune control of multiple
pathogens and cancers. As shown in Figure 2.3, each virus particle, or virion, contains two
copies of an RNA genome, which are transcribed into DNA in the infected cell and integrated
into the host cell chromosome.
The primary infection with HIV is asymptomatic in 50% of cases but often causes an
influenza-like illness with an abundance of virus in the peripheral blood and a marked drop
in the numbers of circulating CD4 T-cells. This acute viremia is associated in virtually all
patients with the activation of CD8 T-cells, which kill HIV-infected cells, and subsequently
with antibody production, or seroconversion. Infection with HIV generates an adaptive
immune response that contains the virus but only very rarely. Seroconversion is the clearest
evidence for an adaptive immune response to infection with HIV, but the generation of
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Figure 2.3. HIV structure
T lymphocytes responding to infected cells is thought by most experts to be central in
controlling the infection. Both CD8 cytotoxic T-cells and TH1 cells specifically responsive
to infected cells are associated with the decline in detectable virus after the initial infection.
These T-cell responses are unable to clear the infection completely and can cause some
pathology. Nevertheless, there is evidence that the virus itself is cytopathic, and T-cell
responses that reduce viral spread should therefore, on balance, reduce the pathology of
the disease. There are three dominant mechanisms for the loss of CD4 T-cells in HIV
infection. First, there is evidence for direct viral killing of infected cells; second, there is
increased susceptibility to the induction of apoptosis in infected cells; and third, there is
killing of infected CD4 T-cells by CD8 cytotoxic lymphocytes that recognize viral peptides.
The typical course of an infection with HIV is shown in Fig 2.4. However, it has become
increasingly clear that the course of the disease can vary widely. Thus, although most people
infected with HIV go on to develop AIDS and ultimately to die of opportunistic infection or
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cancer, this is not true of all individuals [36].
Figure 2.4. The clinical course of HIV infection [image source: Lehigh University]
Typically, “during primary HIV infection, the viral load in plasma increases rapidly,
reaches a peak, and then declines until it reaches a set point level” [59, 53]. There are
several biological and statistical research studies about the viral growth at the early stage
of HIV infection. In Figure 2.5, we show observerved viral load data and the corresponding
fitted model curves for 10 patients, from [59]. Similarly, Figure 2.6 shows the early viral load
profiles for 15 patients from a different study [53]. In both figures, we can observe the rapid
increase of the viral load soon after infection, followed by a decrease that may be caused by
the immune response or the lack of susceptible cells. Even after this decreaes, the viral load
remains steady, allowing HIV to eventually develop into AIDS. However, we also point out
the wide variability in the data between patients, indicating that at best we can hope to
reproduce the overall qualitative behavior of the infection within any mathematical model.
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Figure 2.5. Theoretical curves using estimated parameters vs. observed viral load data ()
for 10 patients [59].
10
Figure 2.6. Early viral load profiles for 15 patients, showing a viral peak and postpeak decay
[53].
HIV, and AIDS specifically, received severe attention because of its wide spread and mor-
tality. This changed in 1995, with the introduction of protease inhibitors and non-nucleoside
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reverse transcriptase inhibitors (NNRTI) to antiretroviral treatment regimens, that began
the era of highly active antiretroviral therapy (HAART). This treatment promoted the dra-
matic improvement in the mortality and morbidity of HIV, as determined by a decreased
incidence of opportunistic infections, tumors, and deaths. Within only four years, between
1994 and 1998, the incidence of AIDS in Europe was reduced from 30.7 to 2.5 per 100 patient
years. With the development of medical science and abundant research on HIV, there are
approximately 36 antiretroviral drugs on the market, which are generally prescribed and
taken in combinations of 3 or more, with some patients needing to take 30 pills a day to de-
crease the incidence of AIDS. In general, these antiviral particles diminish the viral infections
through different mechanisms [21]. We can summarize these mechanisms in the following
ways:
 diminish the virus’s ability to infect susceptible cells by reducing the infection rate,
and
 diminish virus replication by reducing the number of new virus particles generated by
infected cells.
Despite all the therapeutic advantages achieved during the last decades, once an individual
has been infected, eradication of the virus still remains impossible [32].
One of the primary reasons for the difficulty in eradication of HIV, the latently infected
cells, needs to be mentioned. Latently infected cells, which are a group of infected T-cells
that are not actively producing HIV, represent long-living cellular reservoirs for HIV. After
long-term suppression, HIV still remains detectable in latently infected cells, and nobody
knows how long can these latently infected cells survive. Nevertheless, a small number of
latently infected cells would be sufficient for the infection to blow up as soon as treatment is
interrupted [32]. Cardiac output, which is the amount of blood the heart pumps through the
circulatory system in a minute, of an adult is normally 4.7 liters. Meanwhile, the estimation
of total post-nodal (efferent) flow-rate for lymphatic circulation is around 4 L/day [50]. Thus
we can see that the flow rate of lymphatic circulation is much lower than the blood circulation.
Moreover, there is a zone in the lymph node composed of cortex and paracortex that has
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even lower diffusivity where the latently infected cells could reside. Hence we hypothesized
that this would be a good place to start when studying latent HIV infection.
From the previous discussion, we can see that there are complex reactions between the
development of HIV infection, medicine and T lymphocytes corresponding to adaptive im-
mune response. To quantitatively analyze the clinical course of HIV with medicine in the
human lymph node, we propose a mathematical model consisting of a system of partial dif-
ferential equations (PDEs) to model the reactions among HIV, medicine and T lymphocytes,
as well as the transport of these to and from the lymph node.
Based on the biological characteristics of the lymph node, our model is divided into two
regions:
 the sector Ω1 that comprises the lymph node itself, and
 the sinus region Ω2 surrounding the lymph node, where products are transported to
and from the lymph node.
Due to the higher density of the lymph node in region Ω1, particles primarily move through
diffusion; whereas since Ω2 consists of afferent/efferent lymphatic vessels and medullary
sinus, transport in that region is modeled as an incompressible fluid.
2.1. Ω1 within the lymph node
The immune response of HIV infection in the lymph node is very complex, as is clear
from the previous discussion. To quantitatively study the phenomena, hereby, we need to
integrate the experimental biological data into a mathematical model. From the biological
perspective, we must consider data at various levels of the immune system, as well as immune
interactions with the virus both with and without medicine. On the mathematical side,
we must consider system analysis and computational modeling techniques. Our objective
is to combine these to develop a three-dimensional geometric computational model of viral
dynamics in the lymph node, to allow numerical studies of viral reservoirs causing reinfection
once drugs are stopped.
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For the model in region Ω1, we consider the concentration of the particles at time t
on the spatial location (x, y, z) ∈ Ω1. We analyze the spatio-temporal dynamics of the
concentrations of HIV (V ), medicine (M), chemoattractant (c), T-cells (T ) and infected
cells (I) using an advection-reaction-diffusion system of PDEs.
Our model builds off of a rich history of previous work in the mathematical modeling
of viral infection dynamics. In the next section we briefly summarize the main models on
which our work extends.
2.1.1. Previous models
To construct a model of the human lymph node, both the biological structure and the
function of the lymph node are required. However, although there exist numerous models of
HIV dynamics in the blood, there are only a few that focus specifically on the lymph node
itself.
2.1.1.1. Reaction-diffusion model in lymph node
The first model to study the role of the lymph node structure on HIV is “Reaction-
Diffusion modelling of Interferon Distribution in Secondary Lymphoid Organs” by G. Bocharov
and collaborators in 2011, that proposed a quantitative model of reaction-diffusion type to
examine the distribution of interferon-α (IFNα) in a lymph node [12].
Interferon-α is an interferon produced by various white blood cells that inhibits viral
replication, suppresses cell proliferation and regulates immune response, and that is used in
a form obtained from recombinant DNA to treat hairy cell leukemia, AIDS-related Kaposi’s
sarcoma, condylomata acuminata, and certain chronic hepatitides [49].
The efficacy of immune responses relies on a productive interaction between antigen-
presenting cells (APCs) and lymphocytes. APCs protection by interferon requires that
the in situ IFNα concentration should exceed a certain threshold, which was Bocharov’s
motivation for studying the distribution of interferon-α in the lymph node.
In the first part of their paper, the authors apply a quantitative model to measure the ki-
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netic parameters of the interferon response using experimental data. The high-resolution
data comes from the well-described mouse hepatitis virus infection and a set of delay-
differential equations describing the interaction between the virus, plasmacytoid dendritic
cells and macrophages.
Afterwards, the authors proposed their reaction-diffusion model of IFN dynamics by
considering the concentration of the interferon I at time t on position x ∈ Ω ⊂ R3. Here Ω
is the spatial region occupied by the lymphoid organ. Their model has the form
∂I
∂t




In the model, the authors state that: “D stands for the diffusion mass transfer tensor
which is assumed to be a scalar constant coefficient depending on the subdomain (D =
Di · I, i = 1, . . . , N) since diffusion is considered to be isotropic. The term −dII(x, t) is used
to describe the degradation of interferon, and IFNα secretion by different types of activated
cells located at some position (xlk)
l=1,L
k=1,Kl
is represented by the source term. This source term
is the sum over Dirac delta functions, Fl(x) =
Kl∑
k=1
ρlδ(x−x(l)k ), with ρ(l) representing the per
capita cell type specific secretion rate. Due to the singularity of Fl(·) the equations are to
be understood in the weak sense. ” For the domain Ω these authors used the domain of a
paradigmatic secondary lymphoid organ as shown in Figure 2.7. Functionally, their lymph
node consists of three major subdomains [12]:
 an outer antigen-sampling zone (subcapsular sinus, trabecular sinuses, conduit tubes),
referred to as subdomain Ω1 [this is similar to our sinus region, Ω2],
 B-cell follicles which make subdomain Ω2 [this forms the majority of our lymph node
region, Ω1],
 T-cell zone (cortex and paracortex) denoted as subdomain Ω3 [this forms a small,
higher-density portion of our lymph node region, Ω1].
It is noteworthy that the B-cell zone is considered to have a larger hydraulic conductivity
than the T-cell zone. Although direct measurements of the hydraulic conductivity with the
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T-cell area are missing, it is likely that both diffusion and convection are extremely low [12].
Hence their diffusion coefficients obey the ranking: D1  D2  D3.
Figure 2.7. schematic representation of a paradigmatic secondary lymphoid organ. [12]
These authors used the Open CASCADE technology (see http://www.opencascade.org)
to construct the 3D geometric model for the paradigmatic lymph node in their paper, as
shown in Figure 2.8.
For the numerical results, they only analyzed the steady-state distribution of IFNα across












I(x, t) + dII(x, t) = F (x),
where D = Di · I in x ∈ Ωi, i = 1, 2, 3, and F (x) =
K∑
k=1
ρ δ(x − xk). They completed their
model using homogeneous Neumann boundary conditions.
Their study results suggest that the spatial stationary distribution of IFNα is essen-
tially heterogeneous across the lymph node. This result implies that for some infections the
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Figure 2.8. Reconstruction of the 3D geometry of the secondary lymphoid organ. [12]
pathogens can escape the IFNα effect if the infected target cell are localized, and/or migrate
into poorly protected SLO (Secondary lymphoid Organs) regions [12].
Despite their simplistic domain and study of only the steady-stage concentration of IFNα,
this paper was the first to propose a reaction-diffusion PDE model that realized the impor-
tance of lymphatic structure for understanding particle dynamics in lymph nodes.
2.1.1.2. Mathematical model of viral infection dynamics
The second paper we discuss is “Mathematical modeling of viral infection dynamics in
spherical organs” by R. Dunia and R. Bonnecaze in 2013 [21]. In this work the authors
present a general mathematical model of viral infections inside a spherical organ. Trans-
ported quantities are used to represent external cells or viral particles that penetrate the
organ surface to either promote or combat the infection. A spherically-symmetric diffusion
mechanism is considered for the migration of transported quantities to the inner organ tissue.
Although this diffusion model and geometry are simplistic, the paper provides an excellent
mathematical model of interacting processes within such organs. Cases that include the
effect of penetration, diffusion and proliferation of immune system cells, the generation of
latently infected cells and the delivery of antiviral treatment are analyzed. In addition,
different antiviral mechanisms are modeled in the context of spatial variation [21].
This work assumes that virus particles are initially circulating through the blood stream,















where S = [S1 S2 · · · Sm]T is a vector of stationary variables, and T = [T1 T2 · · · Tl]T
represents a vector of transported variables. The evolution equations for the stationary vari-








where F is a vector of nonlinear functions that represent the generation-consumption terms
of the stationary variables. Such a function provides the rate of proliferation and mortality of









models the radial diffusion. Finally, the
vector function G denotes the generation-consumption terms for the transported variables.
The model is analyzed in several different ways, including:
 the basic virus model in the absence of immune cells,
 the effect of the immune system in the infected organ as an external agent,
 the distinction between productively and latently infected cells, and
 different antiviral mechanisms of action.
In the basic model for virus dynamics analysis, the authors only considered S = [X Y ]T
where X and Y denote uninfected and infected cells, respectively, and T = V represents free













= kY − uV.
Here, λ represents the generation of new uninfected cells, d represents the death rate of
uninfected cells, β represents the infection rate by the virus, a represents the death rate of
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infected cells, k represents the release rate of virus from infected cells, and u represents the
death rate of the virus. The results illustrate the radial distribution and predict the effect
of physical parameters on the propagation of a viral infection through a spherical organ in
the absence of an immune response.
Then, the model considers immune cells as transported quantities that penetrate the
infected organ with a rate proportional to the number of infected cells at the organ surface.






 λ− dX − βXV







 kY − uV
cY Z − bZ
 ,
where S = [X Y ]T and T = [V Z]T . Here, p represents the infected cell elimination rate
by the immune cells, c represents the generation rate of immune cells, and b represents the
death rate of immune cells.
The authors then expanded their study to include the latently infected cells as we de-







λ− dX − βXV
qβXV − aY − pY Z + αYL










for S = [X Y YL]
T and T = [V Z]T , and where YL denotes the latently-infected cells. In
the model, q represents the portion of productively infected cells, α represents the activation
rate of latently-infected cells, and αL = 0.2α.
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Finally, the effect of antiviral drug therapy is considered. This effect was applied in
two ways: (a) reduce the virus’ ability to infect susceptible cells, and (b) suppress viral
replication-production in infected cells. The population of antiviral particles is a transported
quantity denoted by W with no generation term inside the solid organ. Including these







λ− dX − βWXV
qβWXV − aY − pY Z + αYL












with S = [X Y YL]
T and T = [V Z W ]T . Here, βW and kW denote the infection
rate by the virus and the release rate of virus from infected cells under antiviral therapy,
respectively. g represents the virus elimination rate by antiviral particles, and e represents
the clearance rate of antiviral particles.
A particular contribution of this model is that it gives the flexibility to consider the
significant variety of infection cases step by step, including some ideas about the usage of
medicine throughout the clinical course of infection. While the previous study by Bocharov
and collaborators indicated the need for a PDE model that includes the spatial inhomogeneity
of the lymph node, this model clearly illustrated the need to include a larger set of complex
interactions between free virus, immune cells, infected (and latently infected) cells, and
medicine.
2.1.1.3. Chemotaxis
The last work we need to refer to is not just a single paper, but a framework that has
been developed since the 1970s. As we see from the previous two papers, the movement
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of particles in the lymph node is typically modeled using diffusion. However, as a part
of the adaptive immune system, T-cells also undergo oriented migration, chemotaxis, as
an essential feature of the immune response [9]. Chemotaxis is the influence of chemical
substances in the environment on the movement of mobile species [33]. As shown in Figure
2.9, the movement towards a higher concentration of the chemoattractant is termed positive
chemotaxis and the movement towards regions of lower chemorepellent is called negative
chemotactical movement [33].
Figure 2.9. Oriented migration
To study this phenomena mathematically, we consider c(x, t) to be the concentration of
chemoattractant at time t in position x, and we consider T (x, t) the concentration of the
moving cells. The classical chemotaxis model is the Keller-Segel model [38, 39], proposed by
E. F. Keller and L. A. Segel in the 1970s, which consists of four coupled reaction-advection-
diffusion equations. By reducing their model under quasi-steady-state assumptions, we arrive
at the general form [30],
Tt = ∇ · (k1∇T − k2T∇c) + k3
ct = ∇ · (Dc∇c) + k4 − k5c
where each of the terms ki = ki(T, c); k1 describes the diffusivity of the cells, k2 is the
chemotactic sensitivity, k3 describes cell growth and death, and k4 and k5 are kinetic functions
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that denote production and degradation of the chemical signal, respectively.
We note that solutions of the Keller-Segel model do not always globally exist, and nu-
merous researchers have studied solvability conditions for the Keller-Segel model. Here we
highlight one conclusion [65]. Consider the minimal Keller-Segel model with homogeneous
Neumann boundary conditions and given initial condition,
ut = ∆u−∇ · (u∇v), x ∈ Ω, t > 0, (2.1a)






= 0, x ∈ ∂Ω, t > 0, (2.1c)
u(x, 0) = u0(x), v(x, 0) = v0(x), x ∈ Ω, (2.1d)
in a bounded domain Ω ⊂ Rn, with initial functions u0 ∈ C0(Ω̄) and v0 ∈ C1(Ω̄) assumed to
be nonnegative. The results from [65] state that:
 if n = 1, then all solutions of 2.1 are global in time and bounded;
 if n = 2, then
− in the case
∫
Ω
u0 < 4π, the solution will be global and bounded,
− for any m > 4π satisfying m /∈ {4kπ | k ∈ N} there exits initial data (u0, v0) with∫
Ω
u0 = m such that the correponding solution of (2.1) blows up either in finite
or infinite time, provided Ω is simply connected;
 if n ≥ 3,
− given any q > n
2
and p > n one can find a bound for u0 in L
q(Ω) and for ∆v0 in
Lp(Ω) guaranteeing that (u, v) is global in time and bounded,
− Ω is a ball then for arbitrarily small mass m > 0 there exist u0 and v0 having∫
Ω
u0 = m such that (u, v) blows up either in finite or infinite time.
However, we believe that in the context of our problem, the solution will not blow up
since we do not have an infinite supply of T-cells in the domain Ω.
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2.1.2. Our model
Based on the aforementioned work we now propose our own model, where we consider
the concentration of HIV (V ), medicine (M), chemoattractant (c), T-cells (T ) and infected
cells (I).
Figure 2.10. sector Ω1
We begin with the lymph node region Ω1, corresponding to both the “B-cell” and “T-
cell” regions of the Bocharov model described in Section 2.1.1.1. Our schematic of this
region is shown in Figure 2.10, where the lower-density “B-cell” region is shown in blue,
and the higher-density “T-cell” region is shown in orange. All of the modeled particle
concentrations are transported through diffusion in the region Ω1, except the T-cells that
undergo advection-diffusion due to chemotaxis, as described above. Thus DV , DM , Dc, DT ,
and DI are the diffusion coefficients for the particles V , M , c, T , and I, respectively. As we
have learned from [12], the hydraulic conductivity varies significantly between the different
zones of the lymph node, and hence these diffusion coefficients are not constant throughout
space. Since diffusion is much slower in the T-cell zone than in the B-cell zone, we should
have DkB zone  DkT zone , for k ∈ {V,M, c, T, I}. Moreover, since T-cells undergo chemotaxis,





is a constant named the chemotactic sensitivity. In addition to the time and transportation
terms in each equation, we also need to include the reaction terms.
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Following the biological mechanisms described above, the interaction of virus with lym-
phocytes and medicine should be taken into consideration. In simple terms, T-cells and
medicine can kill the virus while T-cells are susceptible to infection by HIV. The replication
of virus depends on the amount of infected T-cells, I. Therefore, the coefficient multiplying
the reaction term between virus and lymphocytes in the virus evolution equation is composed
of both the elimination rate of virus by lymphocytes, and the infection rate of T-cells. Math-
ematically, this may be modeled by a reaction term fTV T , where fT is a combination of the
virus elimination rate eT by the T-cells and the infection rate iT of T-cells, i.e., fT = eT − iT .
The coefficient multiplying the reaction term between virus and medicine, eM , is determined
by the clearance rate of the virus by the medicine. Finally, rI denotes the virus replication
rate that multiplies the concentration of infected cells, and dV is the virion clearance rate
constant. Combining these terms, along with our model for spatial diffusion, our model for







= −fTV T − eMVM + rII − dV V.
Similarly, our model for the interaction of medication with the virus must be taken into
account. Thus, we include a eMVM term to represent the elimination of virus by medicine.
Likewise, we model the medicine clearance as having rate constant dM . Combining these
reaction terms with their spatial diffusion, our model for the dynamics of medication particles







= −eMVM − dMM.
Based on working mechanisms of the antiretroviral drugs as discussed previously, the therapy
takes effect in our model in the following ways:
 To diminish the virus’s ability to infect susceptible cells, we reduce the infection rate






where Φ is a constant that determines the effectiveness of the medication in preventing
cell infection. We note that M = 1/Φ represents the 50% inhibitory concentration,
denoted by IC50.
 To diminish virus replication by reducing the number of new virus particles generated
by infected cells, we reduce r. This works through protease inhibitors, and can be





where the larger Ψ (or the smaller the IC50 = 1/Ψ) the more effective M is in reducing
replication in productively infected cells.
We may therefore test different drug combinations by changing the constants Φ and Ψ. We
will examine the effects of these parameters in detail in Chapter 6.
Our model for the concentration of infected T-cells, I, similarly includes a growth term
corresponding to the infection rate of healthy T-cells by the virus, iTV T , as well as a standard








= iTV T − δI.
For the chemoattractant c equation, we follow the classical chemotaxis model, with clear-
ance term λc and chemical signal production term pcV T . Combined with the diffusion of







= −λc+ pcV T.
We lastly consider the reaction network for the healthy T-cell concentration. As we
mentioned before, T-cells mature in the lymph node, corresponding to a source term gT in
the equation due to this maturation rate. Additionally, we include a reaction term −kTV T
between virus and T-cells to model the rate at which healthy T-cells are infected. As always,
there exists a clearance term dTT with death rate dT . Combining these with our advection-







= −kTV T − dTT + gT .
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In summary, our model describes the movement and reaction of virus, immune cells,
medicine and chemoattractant in the human lymph node region Ω1. This corresponds to an



































= −kTV T − dTT + gT . (2.2e)
Each of these variables are functions of (x, t) ∈ Ω1 × [0, tf ] and the equations are defined on
the space
S = U × U × U × U × U (2.3)
where U = H1(Ω1)× I. Here, H1 represents the Sobolev space given by
H1 = {u(x) ∈ L2(Ω1) | ∇u ∈ L2(Ω1)}, (2.4)
and I representes the time space
I = [0, tf ]. (2.5)
The corresponding initial and boundary conditions are specific to each test, and are
discussed as each test is presented in Chapter 5. In Table 2.1.2 we present the full set of
modeling parameters, along with their physical values (and the sources where these were
found). We note that not all of these parameters have been determined experimentally; for
these we show our best guess at the values. We note that from this data we can easily see
the difference of diffusion coefficients in the B- and T-cell regions.
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Table 2.1. Model parameters and variables. Those that vary between the “B-cell” and
“T-cell” regions show two values, denoted by “B” and “T” for the two regions, respectively
(values are based on the lymph node cell density).
Description Value Source
DV virus diffusion coefficient 1 cm
2/day (B), 0.1 cm2/day (T) [21, 12]
DM medicine diffusion coefficient 2 cm
2/day (B), 0.2 cm2/day (T) [21, 12]
Dc chemoattractant diffusion coefficient 0.8 cm
2/day
DI infected T-cell diffusion coefficient 0.1 cm
2/day (B), 0.01 cm2/day (T) [21, 12]
DT healthy T-cell diffusion coefficient 0.1 cm
2/day (B), 0.01 cm2/day (T) [21, 12]
χ the chemotactic sensitivity 1.0
eT virus elimination rate by T-cells 1.65 (µl virion-day
−1)×10−3
iT infected rate of T-cells 0.65 (µl virion-day
−1)×10−3 [59]
fT reaction rate between T-cells and virus 1.0 (µl virion-day
−1)×10−3
eM virus elimination rate by medicine 0.5 1/mol.day [21]
rI virus replication rate from one infected cell 18, 1000 vir/(cell.day), 850 (virion day
−1) [21, 53, 59]
dV clearance rate for free virus 23 day
−1 [53]
dM medicine clearance rate 0.3 day
−1 [21]
λ degradation rate of the chemical signal 0.5 day−1
pc production rate of chemical attractant 0.1 mm
3/(imm cell.day)
δ clearance rate of infected T-cells 0.39 day−1, 0.6 day−1 [53, 59]
dT death rate of T-cells 0.01 day
−1 [59]
gT proliferation rate of T-cells in the lymph node 2 mm
3/(imm cell.day) [26]
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2.2. The sinus region Ω2
The region Ω2 surrounding the lymph node is the area which is composed of the subcap-
sular sinus and afferent/efferent lymphatic vessels, a schematic of which is shown in Figure
2.11. Similar with the model in region Ω1, we consider the concentrations of virus, medicine
and infected/uninfected T-cells, again using the variables V , M , I and T . The subcapsular
sinus receives lymph from the afferent lymphatic vessels and passes it to the cortical sinus.
In this region, particles are delivered to and from the lymph node with the free movement of
lymphatic fluid, whose flow may be best modeled as an incompressible fluid. Therefore, we
combine the Navier-Stokes equations for incompressible flow and conservation of mass with
our reaction modeling terms used in Ω1. However, we remove the modeling terms from (2.2)
that correspond to T-cell generation, since that only occurs inside the lymph node itself, and
we remove the chemoattractant since the T-cells do not undergo chemotaxis in this region.
Figure 2.11. sinus region Ω2
A fluid is said to be incompressible when its density is not changed by external forces
acting on the fluid. In other words, the rate of change of fluid density ρ following the motion




Thus, the fluid density is given by a constant ρ, and when a shear stress is applied to any fluid,
it will deform continuously so long as the shear stress is applied. The viscosity is a measure
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of the resistance of the fluid to flow. The kinematic viscosity measures the resistance to flow
of a fluid under the influence of gravity. Here we denote the constant kinematic viscosity by
ν. Since the virus, lymphocytes and medicine particles all have different sizes, these should
experience different viscosities as they move through the flow. Thus, in the flow model we
introduce the flow velocity field u = u(x, y, z, t) at the spatial location (x, y, z) ∈ Ω2 at the




+∇ · (ρu) = 0.
Including the incompressibility condition, this equation reduces to ∇ · u = 0.







u− ν∇2u = 1
ρ
∇p, (2.6a)




























T − νT∇2T = −kTV T − dTT. (2.6f)
The model in region Ω1 is an advection-diffusion-reaction PDEs to analyze the dynamics
and interactions of the virus, medicine and T-cell concentrations in the dense lymph node,
while the model in region Ω2 is an incompressible flow model to analyze the transport of
these quantities into and out of the lymph node. By coupling the models together, we
can quantitatively study these biological phenomena in the human lymph node to better
understand the effects of various drug treatments for HIV. In the next two chapters we
discuss the numerical methods that we apply to approximate solutions to this model. We
then demonstrate the qualitative and quantitative performance of this model on studying




In this chapter, we present the numerical methods we used to approximate solutions to the
model equations (2.2) in region Ω1. We use the finite element method to discretize the spatial
domain, which leads to a time-dependent nonlinear system of ordinary differential equations
(ODEs). We then apply a variety of ODE solvers to convert the problem to a corresponding
system of nonlinear algebraic equations for each time step. We then solve these nonlinear
systems using a standard Newton’s method supplied with residual and Jacobian. Since
calculation and solution of the corresponding linear systems is computationally costly, we
investigate four different types of preconditioners applied to a standard GMRES iterative
linear solver. Due to the size of the three-dimensional problem and the desire for high-
resolution simulations, all of these algorithms are performed in parallel. The computational
domain is approximated by an unstructed tetrahedral mesh, which will be discussed in
Chapter 5. We separately discuss the details of each aspect of our numerical method in the
following sections.
3.1. Finite element discretization
Consider a triangulation T of the spatial domain Ω1. Then the solution (V,M, c, I, T ) of
the model problem is defined in the space:
S = U × U × U × U × U (3.1)
where U = H1(Ω1)× I. Here, H1 represents the Sobolev space given by
H1 = {u(x) ∈ L2(Ω1) | ∇u ∈ L2(Ω1)}, (3.2)
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and I representes the time space
I = [0, tf ]. (3.3)
We point out that we do not include the boundary conditions in the finite element space
above since we utilize a variety of different boundary conditions in the test problems that fol-
low, where we consider homogeneous Neumann, nonhomogeneous Neumann, homogeneous
Dirichlet and nonhomogeneous Dirichlet boundary conditions. We will discuss these in de-
tail when introducing each test. Here we just consider the simple homogeneous Neumman
boundary conditions for convenience when describing the algorithm.
We can then derive the weak formulation of our model problem using a Galerkin formula-
tion. Let (υ, µ, κ, ι, τ) ∈ S be the test functions corresponding to our solutions (V,M, c, I, T ).





+ 〈DV∇V, ∇υ〉+ 〈fTV T, υ〉+ 〈eMVM, υ〉 − 〈rII, υ〉+ 〈dV V, υ〉






















+ 〈DT∇T, ∇τ〉 − 〈χT∇c, ∇τ〉+ 〈kTV T, τ〉+ 〈dTT, τ〉
= 〈gT , τ〉 ,
(3.4e)
for all (υ, µ, κ, τ) ∈ S. Here we use the notation 〈·, ·〉 to represent the standard L2 inner
product. From finite element view, we take all of these rhs as forcing terms. In our biology
model, there is no rhs term except for the last equation, and thus for our biology tests we
set these to be 0 in practice. However, for some of our other tests, we will manipulate these
rhs terms as needed. For the last T equation, we just simply contain the rhs inside the gT
term.
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We spatially discretize our model by restricting the variational problem (3.4) to a pair of
discrete trial and test spaces. We utilize a Galerkin formulation: find (Vh,Mh, ch, Ih, Ih, Th) ∈





+ 〈DV∇Vh, ∇υh〉+ 〈fTVhTh, υh〉+ 〈eMVhMh, υh〉+ 〈dV Vh, υh〉






















+ 〈DT∇Th, ∇τh〉+ 〈χTh∇ch, ∇τh〉+ 〈kTVhTh, τh〉+ 〈dTTh, τh〉
= 〈gT , τh〉 ,
(3.5e)
for all (υh, µh, κh, ιh, τh) ∈ Sh. Representing the discretized solution (Vh,Mh, ch, Ih, Th) as
u, then the variational problem leads to a nonlinear time dependent system of ordinary
differential equations
N u̇ + A(u) = f(t) (3.6)
where u̇ denotes partial differentiation of u with respect to t, N is a block-diagonal mass
matrix,
AV (u) = 〈DV∇Vh, ∇υh〉+ 〈fTVhTh, υh〉+ 〈eMVhMh, υh〉 − 〈rIIh, υh〉+ 〈dV V, υh〉 ,
AM(u) = 〈DM∇Mh, ∇µh〉+ 〈eMVhMh, µh〉+ 〈dMMh, µh〉 ,
Ac(u) = 〈Dc∇ch, ∇κh〉+ 〈λch, κh〉 − 〈pcVhTh, κh〉 ,
AI(u) = 〈DI∇Ih, ∇ιh〉 − 〈iTVhTh, ιh〉+ 〈δIh, ιh〉 ,
AT (u) = 〈DT∇Th, ∇τh〉 − 〈χTh∇ch, ∇τh〉+ 〈kTVhTh, τh〉+ 〈dTTh, τh〉 ,
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and
fV (t) = 〈rhsV , υh〉
fM(t) = 〈rhsM , µh〉
fc(t) = 〈rhsc, κh〉
fI(t) = 〈rhsI , ιh〉
fT (t) = 〈gT , τh〉 .
We note that the system (3.6) may be equivalently written in explicit first-order form as
u̇ +N−1A(u) = N−1f(t) (3.7)
3.2. Time semi-discretization
After spatial discretization, we must solve a large nonlinear time dependent system (3.6)
or (3.7). Due to the parabolic nature of the model (2.2), we wish to use a stable, efficient
implicit method for the time semi-discretization. In this work, we explore Backward Euler,
singly diagonal implicit Runge-Kutta (SDIRK) and Backward Differentiation formula (BDF)
time integrators.
We perform our numerical implementation of the discretized model (3.7) using the MFEM
library (see http://mfem.org). MFEM is a free, lightweight, scalable C++ library for finite
element methods [2]. MFEM has built-in operators for both diffusion and convection which
we use for the diffusion and chemotaxis components of the bilinear forms in our model.
However, MFEM does not supply built-in operators for reaction terms, so we needed to
implement those components of our model manually within MFEM. Additionally, MFEM
includes native implementations of fixed time-step Backward Euler and SDIRK methods, as
well as interfaces to the SUNDIALS library ([31], see https://computation.llnl.gov/projects/
sundials), that includes the CVODE and ARKODE solvers for temporally-adaptive BDF and
SDIRK methods, respectively. We discuss our use of these software packages later on, in
Section 3.2.3.
33
3.2.1. General comments on implicit methods
Time integration methods for problems of the form (3.6) or (3.7) construct approximate
solutions un ≈ u(tn) at the discrete set of times t0 < t1 < . . . < tM , where tn+1 − tn = kn.
When using an implicit method to traverse the time step tn → tn+1, we first convert the fully
discretized system to an equivalent root-finding problem, F (u) = 0 (the solution of which
is the time-evolved solution, un+1). We then apply Newton’s method to solve this problem:
given an initial guess u(0) to u, this constructs iterates








, q = 0, 1, . . . .
These iterations are stopped when the estimated solution error ‖u(q+1)−u(q)‖ is small. Thus
in order to apply Newton’s method, we must provide the following items:
(a) the nonlinear root-finding function F : Rm → Rm,





















for the explicit form of the problem (3.7), where the value of γ depends on the time
integration method under consideration, and


















In this work, we utilize a preconditioned Generalized Minimum Residual (GMRES) method
[56] for item (c) above, and discuss our preconditioning strategies in Chapter 4. Each specific
time integration method will have slightly different formulations of F and values for γ, which
we discuss one by one in the following sections.
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3.2.2. Backward Euler and SDIRK
The Backward Euler method approximates the ODE u′(t) = g(t,u) over a time step
tn → tn+1 as un+1 − un = kng(tn+1,un+1). Applying this to our original time-dependent
problem (3.6), we have the nonlinear residual function
F (u) = Nu + γknA(u)− γknf(tn+1)−Nun,


























































Similarly, for the explicit form of the time-dependent problem (3.7), we have the nonlinear
residual function
F (u) = u + γknN
−1A(u)− γknN−1f(tn+1)− un



























































Mathematically, the Backward Euler method is stable and consistent. The method has
accuracy O(kn), which is convergent but not efficient. We, therefore, use Backward Euler to
verify correctness of the code and compare against the other methods for order of accuracy.
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Similar to the Backward Euler method, an SDIRK method is a one-step method with







cs as1 as2 · · · γ
b1 b2 · · · bs
for s stages. To apply the SDIRK method to an ODE of the form Nu′(t) = g(t,u), one must
compute
Nzi = Nun + kn
i∑
j=1
aijg(tn,j, zj) i = 1, . . . , s




where the stage times are given by tn,j = tn + cjkn. Thus, for each stage i, we define the
nonlinear residual function
F (z) = Nz + γkn (A(z)− f(tn,i)) + kn
i−1∑
j=1



























































MFEM has the built-in solvers SDIRK34 and SDIRK33. The SDIRK34 solver is a three













+0.5 and b =
1
6(2a− 1)2
. This SDIRK34 method is A-stable but not




1 b 1-a-b a
b 1-a-b a
for a = 0.435866521508458999416019, b = 1.20849664917601007033648, and
c = 0.717933260754229499708010.
3.2.3. SUNDIALS solvers
As we mentioned above, MFEM has an interface to the SUNDIALS package. SUNDIALS
consists of six solvers: CVODE, CVODES, ARKODE, IDA, IDAS and KINSOL. Here we
used CVODE, a solver for initial value problems for ordinary differential equation (ODE) sys-
tems, and ARKODE, a solver for initial value problems with additive Runge-Kutta methods,
that includes support for IMEX methods.
CVODE solves ODE initial value problems (IVPs) of the form u′(t) = g(t,u) using






βn,ig(tn−i,un−i) = 0. (3.10)
For stiff problems, CVODE includes the Backward Differentiation Formulas (BDF) in so-
called fixed-leading coefficient (FLC) form, given by K1 = q and K2 = 0, with order q varying
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between 1 and 5. Then the nonlinear system (3.10) can be formulated as the root-finding
problem





Similarly, ARKODE solves ODE initial value problems Nu′(t) = g(t,u) using addi-
tive Runge-Kutta methods by separating the right-hand side function into nonstiff compo-
nents gE(t,u) and stiff components gI(t,u). Writing the IVP system in the form Nu
′(t) =
gE(t,u) + gI(t,u), then applying variable-step, embedded, additive Runge-Kutta methods
results in the equations










n,j, zj), i = 1, . . . , s,


























Here ũn are embedded solutions that approximate u(tn), and that are used for error esti-
mation in order to adapt the time step size kn. While ARKODE supports IMEX methods,
MFEM only provides an ARKODE interface for purely explicit or implicit solvers. Consid-
ering our model in this thesis, we use the implicit solvers from ARKODE, corresponding to
the choice gE = 0, and resulting in SDIRK methods. As a result, our nonlinear residual and
Jacobian functions match those in equations (3.8) and (3.9).
3.3. Implementation in MFEM
We used a variety of software packages when implementing our model. First, to create
the mesh we employed the Gmsh package (see http://gmsh.info), a three-dimensional finite
element mesh generator with built-in pre- and post-processing facilities [27]. As previously
stated, we implemented our finite-element approximation, including time integrators, nonlin-
ear solver, linear solver, and preconditioners using the MFEM finite element infrastructure
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[2]. It enables research and development of scalable finite element discretizations and solver
algorithms through general finite element abstractions, accurate and flexible visualization,
and tight integration with the hypre library (see http://www.llnl.gov/casc/hypre), that pro-
vides scalable multigrid methods for large-scale linear systems of equations. Conveniently,
MFEM can directly read the Gmsh-generated .msh finite element mesh files.
Given the Gmsh-generated .msh file defining our computational domain Ω1, our MFEM-
based implementation of the model (2.2) proceeded by the following steps:
1. Construct the finite element discretization:
(a) Import the Gmsh mesh file.
(b) Define a finite element space on the mesh with an H1 finite element collection of
order p. Our default value is p = 1, but this may be modified with a command-line
option.
2. Define the type of time discretization method to use. MFEM provides different types
of time integration methods to choose from. Both MFEM’s built-in implicit time
integration methods and SUNDIALS solvers (ARKODE and CVODE) are tested. It
is easy to switch the ODE solver as long as we set the Jacobian correctly.
3. Construct the boundary conditions:
(a) Mark degrees of freedom corresponding to boundary locations with values indi-
cating the type of boundary condition to apply (0=Neumann, 1=Dirichlet).
(b) For non-homogeneous Dirichlet/Neumann conditions, supply a function to provide
the corresponding boundary condition value based on the location of the degree
of freedom.
4. Define the block structure of the problem by setting the array of offsets for each vari-
able. Get the number of vector degrees of freedom from the finite element space, and
allocate our array u of this length.
5. Allocate the relevant grid functions, coefficients, and vectors with their associated
finite element space. We relate the grid function with the block vector u by making a
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reference to the corresponding data. We allocate several coefficients. Initial conditions
of the system are used to initialize the function coefficients and the grid function. Also,
the parameters in our model are defined using constant coefficients. In the code, we
refer to −eM by a12 and a21, rI by a14, −fT by a15, pc by a31, iT by a41, −kT by
a51, −dV by b1, −dM by b2, −λ by b3, −δ by b4 and −dT by b5.
6. Create the time-dependent operator C++ class (derived from the MFEM abstract base
class, TimeDependentOperator):
(a) Define the nonlinear system (3.6). We are using finite element method to do
the spatial discretization and write our system to the ODE (3.6). In our time-
dependent operator C++ class, we define the bilinear form, the nonlinear form
and the corresponding linear form to construct the ODE system.
(b) Define the nonlinear residual function F (u).
(c) Define the corresponding Jacobian function, JF (u).
(d) Define the type of nonlinear solver. We used the MFEM built-in Newton solver,
and provided our residual Jacobian functions, F (u) and JF (u).
(e) Define the type of linear solver. When solving the nonlinear system with Newton
method, each iteration requires the solution of a linear system. Since our system
is nonsymmetric, we chose to apply GMRES.
7. Create the preconditioner. Since our system of advection-reaction-diffusion PDEs is
challenging for GMRES to solve on its own, we tested different types of preconditioners.
To this end, we leveraged MFEM’s support for specialized block preconditioners as a
user-defined solver. We discuss these further in Chapter 4.
8. The last step is evolving the model over the time interval [0, tf ]. We used both fixed-
step methods and the adaptive-step solvers from SUNDIALS.
(a) For the fixed-step method, we tested with Backward Euler. It is easy to set the
fixed time step to be used for each simulation before integration in MFEM.
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(b) For the CVODE/ARKODE solvers, we needed to develop SUNDIALS-specific
functions to set up and perform the implicit solve in the TimeDependentOperator.
Then in the main code, we needed to define the accuracy tolerances and the types




As discussed in Chapter 3, after discretization in space, our model reduces to a large
nonlinear time dependent ODE system (3.6). Applying any of the implicit time integration
methods discussed in Section 3.2, we must in turn solve at least one large nonlinear system
of algebraic equations per step tn → tn+1. For these, we use Newton’s method, which at
each iteration must solve a large nonsymmetric linear system of equations
JF δu = −F,
where JF = [jlk] is an n× n coefficient matrix and −F a given right-hand side vector.
Solving this system is the central, and often the most computationally time-consuming
part in the numerical simulation. For this purpose, there are a variety of methods, which,
generally speaking, are divided into two main classes, direct methods and iterative methods.
Direct methods, based on a factorization of the coefficient matrix JF into easily invertible
matrices, are very robust. These typically include Gaussian elimination, LU decomposition,
and QR factorization. But direct methods demand a large amount of time and storage
when JF is large. Therefore, we focus on iterative methods, such as Gauss-Seidel, SOR and
Krylov subspace methods. Here, preconditioning techniques must be used to improve the
performance and reliability of Krylov subspace methods.
There are several different types of preconditioners that have been developed for multi-
physics systems of equations, and the essential requirements of a good preconditoner are:
 the preconditioned system should be easy to solve using the Krylov method, and
 the preconditioner should be cheap to construct and apply [10].
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4.1. Preconditioners in our model
As we discussed in Chapter 3, in all of the considered time integration methods we
must solve linear systems with the Jacobian JF (u) arising in Newton’s method, u
(q+1) =



























































and the time-dependent Jacobian is either
Jtime(u) = N + γkn
∂A
∂u





















































for our standard form of the time-dependent problem (3.6), or for the problem in explicit
form (3.7) the Jacobian is
Jtime(u) = I + γknN
−1∂A
∂u
























































It is noticeable that all of these Jacobian matrices only differ by a mass matrix N and a
scalar γkn. Hence, similar preconditioners can be applied.
With regards of the structure of our model, we consider preconditioners based on block
matrix decompositions of the Jacobian. Based upon our model, all (V,M, c, I, T ) equations
have diffusion and reaction components, but only the equation for T includes chemotaxis.
Hence, there are diffusion terms, reaction terms and a chemotaxis term in the matrix A(u).
Therefore, we consider a decomposition of our Jacobian into the block form:
J =

jV V jVM jV c jV I jV T
jMV jMM jMc jMI jMT
jcV jcM jcc jcI jcT
jIV jIM jIc jII jIT









jV V jVM jV c jV I
jMV jMM jMc jMI
jcV jcM jcc jcI



















Here, M contains diffusion terms along the diagonal, and the off-diagonal block matrices
only involve inter-variable couplings due to the reaction terms. Similarly, U contains only
reaction terms, L contains both reaction terms and the advection of T based on chemo-
taxis (inside jTc). Finally, D contains reaction, diffusion and advection terms encoding
the dependence of AT (u) on T . Based on this block structure, we consider three types of
preconditioners: block diagonal, lower triangular, and Schur complement. Each of these
preconditioners are discussed in the following subsections.
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For ease of notation, in the remainder of this chapter we will denote the block structure
of our Jacobian as
J =

j11 j12 j13 j14 j15
j21 j22 j23 j24 j25
j31 j32 j33 j34 j35
j41 j42 j43 j44 j45
j51 j52 j53 j54 j55

. (4.2)
4.1.1. Block diagonal preconditioner
















As we can see from the structure of this preconditioner, it would be costly to compute













where j̃11, j̃22, j̃33, j̃44 and j̃55 contain only the diffusion and mass matrix contributions from
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M . Here we have
M − M̃ =

j11 − j̃11 j12 j13 j14
j21 j22 − j̃22 j23 j24
j31 j32 j33 − j̃33 j34
j41 j42 j42 j44 − j̃44

corresponding to the Jacobian components arising from the neglected reaction terms, and




is the Jacobian component arising from the neglected reaction and advection terms.










4.1.2. Lower triangular preconditioner






















However, due to the computational costs associated with inversion of M we again approxi-










where j̃−1ii are the same as in the previous subsection. Here, we first approximate
L =
[





0 0 j̃53 0
]
,
where j̃53 contains the Jacobian terms related to chemotaxis of T , and
L− L̃ =
[
j51 j52 j53 − j̃53 j54
]
only contains the Jacobian components related to reaction terms. Then we approximate the
lower triangular component −D−1LM−1 by














0 0 −j̃−155 j̃53j̃−133 0
]
.
Putting these together, we have










j11 − j̃11 j12 j13 j14
j21 j22 − j̃22 j23 j24
j31 j32 j33 − j̃33 j34
j41 j42 j42 j44 − j̃44
j51 j52 j53 − j̃53 j54 j55 − j̃55

which again corresponds to only the Jacobian components related to reaction terms.
4.1.3. Schur complement
We note that for the block decomposition (4.2) of our matrix JF , the exact Schur com-




























Unfortunately, the cost of computing (and even storing) S−1 is extremely high, so we ap-
proximate the true Schur complement in two different ways. For our PSchur 1 preconditioner,
we first approximate the Schur complement as S̃ = D̃, where, as previously, D̃ contains only
the diffusion and mass matrix contributions from j55. And for our PSchur 2 preconditioner,
we use the slightly more costly approximation Ŝ = D̃ − L̃U where these D̃ and L̃ are the
same as in the previous subsection. For both approaches, we again approximate M by the
block-diagonal version containing only diffusion and mass-matrix contributions, M̃ .























where Ŝ = j̃55, and S̃ = j̃55 − j̃53j35.
4.1.4. Block solvers
In the implementation, we solve each block, e.g., j̃−1ii in MFEM using the BoomerAMG
algebraic multigrid solver from the hypre library. As we discussed previously, we analyzed
the structure of our Jacobian and construct the corresponding preconditioners. MFEM
allows the user to provide customized preconditioners as a derived C++ class from the
generic MFEM Solver class. We can provide our Jacobian as an operator and access each
block through this operator. For scalable preconditioners solving, we use BoomerAMG in hypre
as the preconditioner and GMRES as the solver.
4.2. Scalability of the preconditioners and Matlab tests
We first focus on the algorithmic scalability of these preconditioning approaches, i.e.,
whether the number of iterations required for the preconditioned Krylov method to converge
remains nearly constant as the spatial mesh is refined, or equivalently, whether the number
of nonunitary eigenvalues of the preconditioned matrix is almost constant despite the size of
the matrix.
It has already been proven that for spatial discretization of certain types of PDEs, multi-
grid methods exhibit h-independent convergence [13, 52]. However, this theory does not gen-
erally apply to block linear systems such as those encountered here. While we were unable
to provide theoretical proof of algorithmic scalability for our block systems, in the following
we summarize results from related work suggesting the scalability of our proposed precon-
ditioners and performe numerical tests with similarly-structured one- and two-dimensional
problems in Matlab to show that our preconditioned systems are algorithmically scalable.
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4.2.1. Block preconditioners
The paper “Block preconditioners for coupled physics problems” by Howle and collab-
orators [34] provides a closely-related study to our work. There, under a specific set of
assumptions (which we discuss in detail momentarily) on their problems, the authors ana-
lyze eigenvalue bounds on block diagonal and block upper triangular preconditioners.
The first test problem that they consider is the Bidomain equations, that consist of a
reaction-diffusion system of PDEs coupled to the Fitzhugh-Nagumo equation. This problem









and they name these blocks as A = Ki +
1
∆t
M , B = C = Ki, and D = Ke +Ki.
For this problem the authors state that ∃α ∈ (0, 1) such that
2|(Bv, u)| ≤ α((Au, u) + (Dv, v)), ∀ v, u ∈ Rk, (4.3)
and they prove that κ(APD) ≤
1 + α
1− α
. Here κ denotes the ratio of the maximum real
parts of the eigenvalues of a given matrix to the minimum real parts of the eigenvalues, and
PD is a diagonal preconditioner. Thus with the block-diagonal preconditioner, the right-
preconditioned matrix has condition number that is bounded independently of the mesh
size, indicating algorithmic scalbility of the method.
The second test problem considered by Howle and collaborators is the Bénard convection
problem. This problem consists of the incompressible Navier-Stokes equations coupled to a
convection-diffusion equation for the temperature. The system is
−∆u+ u · ∇u+∇p = −Ra
Pr
ĝT
∇ · u = 0
− 1
Pr
∆T + u · ∇T = 0,
with fluid velocity u and pressure p. The Rayleigh number Ra measures the ratio of energy
from buoyant forces to viscous dissipation and heat conduction, the Prandtl number Pr
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measures the ratio of viscosity to heat conduction, and ĝ denotes a unit vector along the
axis in which gravity acts.
The authors prove that the real parts of the eigenvalues of the Bénard convection system
with a block diagonal preconditioner are given by




‖∇T h0 ‖∞ ‖A−1‖L(X′h,Xh),
where Cp represents the constant from Poincaré’s inequality, ‖∇T h0 ‖∞ is the usual infinity
norm of the initial discretized temperature gradient, and the ‖A−1‖L(X′h,Xh) term has a mesh-
independent bound that depends on ‖u0‖H10 , amongst others.
If we apply the block upper triangular preconditioner to a generalized matrix A =A B
C D











CA−1 I − CA−1BD−1
 .
The authors also prove that: the eigenvalues of CA−1BD−1 for the Bènard convection prob-
lem are bounded by
R(λ) ≤ 1 + (Cp)4
Ra
Pr
‖∇T h0 ‖∞ ‖A−1‖L(X′h,Xh) ‖D
−1‖L(W ′h,Wh).
Here, the authors prove that with the block-diagonal and block upper triangular precondi-
tioners, the eigenvalues of the right-preconditioned matrix are bounded independently of the
mesh size.
Thus in their work, Howle and collaborators prove that for two specific problems, the
eigenvalues are bounded indenpendently of the mesh size for a right-preconditioned ma-
trix with block diagonal and block upper triangular preconditioners. As our problem is an
advection-reaction-diffusion system of PDEs which is similar in structure to these two spe-
cific problems, and we also apply block diagonal and block triangular preconditioners, then
their proof suggests that our preconditioned system may also be algorithmically scalable.
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4.2.2. Matlab tests
As we discussed previously, we would like for our preconditioned system to be algorith-
mically scalable. In the absence of rigorous theory to this end, we chose to investigate
this question with some numerical tests using similarly-structured one- and two-dimensional
problems in Matlab. Although our target application is time-dependent, we perform these
Matlab tests on steady-state problems to examine the most challenging case for these pre-
conditioners (since the linear system becomes simpler to solve as hn → 0, whereas the
steady-state problem corresponds to hn → ∞). For these tests, we compute the condition
numbers of the preconditioned Jacobian matrices as the spatial mesh size is refined. If the
condition number of the preconditioned matrix remains close to one with mesh refinement,
then we believe that the corresponding preconditioning approach will be promising for our
target application.
We tested matrices with no preconditioning and with each of the preconditioning ap-
proaches outlined in Section 4.1: block-diagonal, block lower triangular, ‘perfect’ Schur
complement, and two approximations of the Schur complement.
Our target problem is an advection-diffusion-reaction model, so we should choose the test
problems with advection, diffusion, and reaction term in the matrices. Our corresponding
1D Matlab test problem is:
u′′ + v′2 + uv = 2 + et(et + t2), u(0) = 0, u(1) = 1 (4.4a)
v′′ + u′ − v = 2t, v(0) = 1, v(1) = e. (4.4b)
In this test problem, u′′ and v′′ are diffusion terms, uv is a reaction term, v′2 and u′ are
advection terms, and −v is the mass term, thus this test problem has a similar structure to
our target model. We linearized this model for our tests around u = v = 0.The condition
numbers corresponding to each preconditioning approach are shown in Table 4.1.
52
Table 4.1. Condition numbers of preconditioned matrices for the 1D test problem (4.4).
preconditioner
# of nodes
5 50 100 500 1000 2000
original matrix 70.7 5.89e+3 2.33e+4 5.77e+5 2.31e+6 9.22e+6
block diagonal 1.62 2.08 2.11 2.13 2.13 2.14
lower triangular 1.01 1.00 1.00 1.00 1.00 1.00
Schur (perfect) 1.00 1.00 1.00 1.00 1.00 1.00
Schur type 1 1.01 1.00 1.00 1.00 1.00 1.00
Schur type 2 1.00 1.00 1.00 1.00 1.00 1.00
Our 2D Matlab test problem is:
−∇2u+ u+ v = −2[x(x− 1) + y(y − 1)] + x(x− 1)y(y − 1) (4.5a)
+ sin(πx) sin(πy)
−∇2v − u− v −∇ · h(v) = 2π2 sin(πx) sin(πy)− x(x− 1)y(y − 1) (4.5b)






. Similarly, we also include diffusion, advection, and reaction terms in
this test problem. The corresponding condition numbers for each preconditioned matrix are
shown in Table 4.2.
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Table 4.2. Condition numbers of preconditioned matrices for 2D test problem (4.5).
preconditioner
# of nodes
262 742 9942 37862 58822
original matrix 11.6 16.2 1.73e+2 7.01e+2 1.13e+3
block diagonal 1.03 1.03 1.03 1.03 1.03
lower triangular 1.10 1.17 1.25 1.26 1.21
Schur (perfect) 1.00 1.00 1.00 1.00 1.00
Schur type 1 1.01 1.00 1.01 1.01 1.01
Schur type 2 1.00 1.01 1.01 1.01 1.01
From these data, we clearly find that the condition number of the un-preconditioned
matrices increase rapidly as the mesh is refined. However, for each of the proposed precon-
ditioning approaches the condition numbers of the preconditioned matrices seem to remain
bounded independently of the mesh size, indicating a potential for algorithmic scalability on
our target application. We also note that even the simple block diagonal preconditioner and
block triangular preconditioner perform rather well. As these are significantly less costly
to construct and apply than the Schur complement approaches, we believe that these may
prove to be more efficient for our application.
4.3. MFEM results
Due to the success of our preconditioning approaches on the preceding Matlab test prob-
lems, we applied the four proposed preconditioners on our target application when using
GMRES as the Krylov solver. Again, to predict the effectiveness of each preconditioner on
the ‘worst case’ for our time-dependent model we collect some data from the corresponding
steady-state problem, where we additionally set each rhs to enforce ‘manufactured’ solutions
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+ kTTV + dTT = rhsT . (4.6e)
This test model is on the steady-state of our full model with extra right-hand sides. These
right-hand sides come from the computation of the ‘manufactured’ method. For this model
we chose the exact solution:
V (x, y, z) = sin(x) sin(y) sin(z), (4.7a)
M(x, y, z) = cos(x) sin(y) sin(z), (4.7b)
c(x, y, z) = sin(x) cos(y) sin(z), (4.7c)
I(x, y, z) = sin(x) sin(y) cos(z), (4.7d)
T (x, y, z) = sin(x) cos(y) cos(z), (4.7e)
with nonhomogeneous Dirichlet boundary conditions derived from this exact solution (4.7)
dV (x, y, z) = sin(x) sin(y) sin(z), (x, y, z) ∈ ∂Ω (4.8a)
dM(x, y, z) = cos(x) sin(y) sin(z), (x, y, z) ∈ ∂Ω (4.8b)
dc(x, y, z) = sin(x) cos(y) sin(z), (x, y, z) ∈ ∂Ω (4.8c)
dI(x, y, z) = sin(x) sin(y) cos(z), (x, y, z) ∈ ∂Ω (4.8d)
dT (x, y, z) = sin(x) cos(y) cos(z), (x, y, z) ∈ ∂Ω, (4.8e)
over the domain Ω = [−1, 1]3. We then constructed each right-hand side forcing term, rhs∗
from (4.6) to ensure these solutions (4.7).
55
Table 4.3. Number of preconditioned GMRES iterations for the 3D test problem (4.6)-(4.8).
preconditioner
degrees
of freedom 6240 42835 315745 2420925
original matrix 205 361 563 800
block diagonal 26 22 22 22
lower triangular 21 18 18 18
Schur type 1 20 17 16 16
Schur type 2 21 20 17 16
In MFEM, the problem is linearized around the exact solution since we use the ‘manu-
factured’ method, and we use the BoomerAMG algebraic multigrid solver for each block when
evaluating our preconditioners. As before, we determined the number of GMRES iterations
for the preconditioned linear systems as the mesh was refined, with results shown in Table
4.3. In this table, we see that the iteration numbers increase rapidly with mesh refinement
for the un-preconditioned matrices. Meanwhile, the number of GMRES iterations for each
preconditioned matrix remains almost constant. We point out that the lower triangular and
Schur type 1 preconditioning approaches result in slightly smaller numbers of preconditioned
iterations than the block diagonal and Schur type 2 approaches; however, all preconditioners




In this Chapter, we discuss the various numerical tests we do as preparation for larger-
scale biology tests. More specifically, in the sections that follow we discuss
 the structure of the lymph node and construction of its 3D mesh,
 simulation of chemotaxis phenomena,
 spatial convergence tests on steady state problems using manufactured solution meth-
ods,
 the effect of discontinuous diffusion coefficients on the convergence rate, and
 ODE analysis of the chemical reaction network.
5.1. Lymph node mesh
Figure 5.1 shows a diagram of the human lymph node. The lymph nodes are highly
organized lymphoid structures located at the points of convergence of vessels of the lymphatic
system, an extensive system of vessels that collects extracellular fluid from the tissues and
returns it to the blood [36]. There are seven major subdivisions of the lymph node [43]:
 The lymph node capsule, which surrounds the lymph node [this is our sinus region,
Ω2].
 The subcapsular sinus, which is the initial entryway of lymphatic fluid into the node
via afferent lymphatic vessels [this forms a small portion of our sinus region, Ω2 ].
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Figure 5.1. One view of an idealized compartment in a lymph node [image source: Open-
Learn]
 The lymph node cortex, which is beneath the subcortical sinus, is the location of
primary and secondary lymphoid follicles [this forms a portion of our lymph node
region, Ω1, with large hydraulic conductivity].
– In the absence of immune stimulation, the cortical lymphoid follicles are primary
follicles, composed of small B lymphocytes which may be virgin B lymphocytes
or recirculating memory B cells.
– With antigenic stimulation, antigen recognizing B cells are stimulated to replica-
tion and differentiation. This converts the primary follicle into a secondary follicle
or germinal center.
 The paracortex, the major site of the T-cells, is the region surrounding and beneath
the germinal centers [this forms a portion of our lymph node region, Ω1, with low
diffusivity].
 The medulla, which is composed of medullary cords and medullary sinuses [this forms
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a portion of our lymph node region, Ω1].
 Medullary vessels such as arteries and veins [these form a small portion of our sinus
region, Ω2].
 Afferent and efferent lymphatic vessels [these form a small portion of our sinus region,
Ω2].
It is noticeable in the diagram that there are multiple almost identical regions in the
lymph node, which we call ‘nodules’. The nodules are composed of a lymphoid follicle, a
paracortex and the medullary cords. Each of the nodules is surrounded by the fluid in the
vessels. In this work, we model one nodule as a representative and note that several nodules
could be coupled together to simulate a full lymph node.
We use the software package Gmsh ([27], see http://www.gmsh.info/) to construct our
3D geometric model of the lymph node and to generate our unstructured tetrahedral mesh
for our finite element approximation.
Figure 5.2. 2D mesh of the lymph node
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Figure 5.3. a simple 3D mesh of the lymph node
We note that we generate a finer-resolution mesh close to the follicle to capture the
large change in the diffusion coefficient between the inside and outside of the follicle. As
opposed to just asking MFEM to perform refinement of the coarsest mesh, we construct this
refinement in Gmsh directly so that finer-resolution grids capture the follicle shape.
5.2. Chemotaxis
As we discussed in Chapter 3, we include a model for chemotaxis; in this section we verify
that these modeling terms reproduce the correct behavior. Here, we focus on the Keller-
Segel Model, modifying the relevant terms to match those from our model, and employ
homogeneous Neumann boundary conditions. The reproduced model is:
ut = ∆u−∇ · (u∇v)− u, x ∈ Ω, t > 0, (5.1a)






= 0, x ∈ ∂Ω, t > 0, (5.1c)
u(x, 0) = u0(x), v(x, 0) = v0(x), x ∈ Ω. (5.1d)
We use a simple square domain Ω = [−1, 1]2 and an initial condition for the chemoat-
tractant given by the Gaussian distribution v0 = K2 exp (−K1‖x− xc‖), where K1 and K2
correspond to the radius and height of the Gaussian function, and xc is the center of the
chemoattractant region. Here we simply choose K1 = 4, K2 = 20, and xc = (0, 0). The
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initial condition for the moving cells is given by the constant u0 = 10, which means that u
is homogeneous throughout the domain at the beginning. We simulate for a time span of
[t0, tF ] = [0, 0.5].
Figure 5.4. Simple unstructured triangular mesh used for testing the chemotaxis phenomena.
Here, we use GLVis ([1], see https://glvis.org/) to view the mesh and the solution. GLVis
is a lightweight tool for accurate and flexible finite element visualization, and is included with
the MFEM library.
Initially, the chemoattractant should display a Gaussian distribution, concentrated at the
center of Ω, and the attracting cells should be homogeneous throughout the domain. Since we
use homogeneous Neumann boundary conditions, there is no flux of either quantity through
the boundary. Therefore due to chemotaxis, we expect to see the oriented movement of u
toward the center of Ω, followed by spreading of both fields to a homogeneous steady-state
due to diffusion.
In Figure 5.5 we show the distribution of u and v in the square domain at the initial time
t0 = 0. From the initial condition, u is homogeneous in the domain, and v has a Gaussian
distribution.
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Figure 5.5. Distribution of u (left) and v (right) at time t0 = 0 in the square domain,
showing their homogeneous and Gaussian-distributed initial states, respectively.
In Figure 5.6 we plot the solutions at time t1 = 0.05, which shows that u is moving
oriented corresponding to the chemoattractant v, and so the distribution of u should be
similar to the distribution of v. The equations for u and v include both diffusion and
reaction terms, they will spread out and decay as time goes by. We see that all of the above
expected phenomena are shown in this figure.
Figure 5.6. Distribution of u (left) and v (right) at time t1 = 0.05 in the square domain.
Note the movement of u toward areas of higher concentration of v.
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In Figure 5.7 we plot the concentrations of u and v at the times t2 = 0.1 and t3 = 0.5. As
expected, the motion of u is still determined through diffusion, chemotaxis and decay, while
v changes due to diffusion and decay. The distribution of u and v are becoming homogeneous
quickly as time increases.
Figure 5.7. Distribution of u (left) and v (right) at the times t2 = 0.1 (first row), t3 = 0.5
(second row), respectively. The chemoattractant v diffuses and decays as expected, and the
attracted cells u return to homogeneity as v diffuses.
5.3. Convergence test
As we discussed in Chapter 2, we use an advection-reaction-diffusion system of PDEs
to model dynamics of the particles (virus, medicine, chemoattractant, infected cells and
lymphocytes) in the region Ω1. In this section, we study the steady-state distribution of our
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model with manufactured source terms to examine the spatial convergence of our model.

























+ kTV T + dTT = rhsT . (5.2e)
To verify our implementation, we choose the system of analytical solutions:
V (x, y, z) = sin(x) sin(y) sin(z),
M(x, y, z) = cos(x) sin(y) sin(z),
c(x, y, z) = sin(x) cos(y) sin(z),
I(x, y, z) = sin(x) sin(y) cos(z),
T (x, y, z) = sin(x) cos(y) cos(z),
which in turn requires the forcing functions
rhsV (x, y, z) =(3DV + dV ) sin(x) sin(y) sin(z) + fT sin(x) cos(y) cos(z) sin(x) sin(y) sin(z)
+eM cos(x) sin(y) sin(z) sin(x) sin(y) sin(z)− rI sin(x) sin(y) cos(z),
rhsM(x, y, z) =(3DM + dM) cos(x) sin(y) sin(z) + eM cos(x) sin(y) sin(z) sin(x) sin(y) sin(z),
rhsc(x, y, z) =(3Dc + λ) sin(x) cos(y) sin(z)− pc sin(x) cos(y) cos(z) sin(x) sin(y) sin(z),
rhsI(x, y, z) =(3DI + δ) sin(x) sin(y) cos(z)− iT sin(x) cos(y) cos(z) sin(x) sin(y) sin(z),
rhsT (x, y, z) =(3DT + dT ) sin(x) cos(y) cos(z) + kT sin(x) cos(y) cos(z) sin(x) sin(y) sin(z)
+ χ(cos2(x) cos2(y) + sin2(x) sin2(y)− 4 sin2(x) cos2(y)) sin(z) cos(z),
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and nonhomogeneous Dirichlet boundary conditions
dV (x, y, z) = sin(x) sin(y) sin(z), (x, y, z) ∈ ∂Ω
dM(x, y, z) = cos(x) sin(y) sin(z), (x, y, z) ∈ ∂Ω
dc(x, y, z) = sin(x) cos(y) sin(z), (x, y, z) ∈ ∂Ω
dI(x, y, z) = sin(x) sin(y) cos(z), (x, y, z) ∈ ∂Ω
dT (x, y, z) = sin(x) cos(y) cos(z), (x, y, z) ∈ ∂Ω.
For these convergence tests, we consider:
 the computational domain Ω = [−1, 1]3,
 constant diffusion coefficients, i.e. DV = DM = Dc = DI = DT = 1,
 reaction parameters fT = eM = kT = pc = iT = 1,
 particle growth/clearance rates rI = dV = dM = λ = δ = dT = 1,
 chemotaxis parameter χ = 1.
In the Table 5.3 we show the convergence of each component from our model as the mesh
is refined. Here, N is the total number of unknowns for (V, M, c, I, T ) in the mesh. We
compute the error in each component using the L2 norm. With the 3D box mesh we used
here, N is proportional to h−3. So we use 1/ 3
√
N to estimate h, then estimate the convergence
rate with the formula p =
log(errnew/errold)
log(hnew/hold)
, and measure the overall convergence rate by
using a linear least squares fit. From these results, we estimate the rate of convergence to
be approximately 2. In the Figure 5.8 we show the 3D unstructured tetrahedral mesh used
in this test, corresponding to the value N = 1745. Larger meshes are constructed through
uniform refinement of this mesh.
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Figure 5.8. Coarse (N = 1745) box mesh used in steady-state convergence tests.
Table 5.1. Computed errors in each solution component for the steady-state model (5.2) as
the mesh is refined. We estimate the overall rate of convergence to be approximately 2.18.
absolute error
N 1745 10370 69575 504905 3836045 con. rate
‖Vh − Vex‖ 1.99e-2 5.07e-3 1.30e-3 3.24e-4 8.04e-5 2.14
‖Mh −Mex‖ 2.81e-2 7.08e-3 1.83e-3 4.60e-4 1.15e-4 2.13
‖ch − cex‖ 2.83e-2 7.14e-3 1.83e-3 4.60e-4 1.15e-4 2.14
‖Ih − Iex‖ 2.93e-2 7.10e-3 1.80e-3 4.51e-4 1.12e-4 2.16
‖Th − Tex‖ 4.85e-2 1.14e-2 2.81e-3 6.97e-4 1.12e-4 2.32
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5.4. Discontinuous diffusion coefficient
The lymph node is composed of a number of nearly identical regions which are called
nodules, and the diffusion coefficient is discontinuous in the nodule [12]. We can roughly
separate the nodule into two parts based upon the diffusivity, the T-cell zone inside the follicle
with diffusion coefficient D in, and the rest of the compartment with diffusion coefficient
D out. These diffusion coefficients are such that D out D in.
To test the influence of this discontinuity in the diffusion coefficient, we performed nu-
merical experiments on a single diffusion equation with discontinuous diffusion coefficient.
The test problem is:




Din = 1, if 0 ≤ r2 < 1,
Dout = 1/α, if 1 ≤ r2,
for varying values of α, and right hand side f = −4. Here the jump is at the boundary of the
circle with radius 1, r =
√
x2 + y2, and u is a general variable which can represent the virus,
immune cells or infected cells. In these tests we used nonhomogeneous Dirichlet boundary
conditions corresponding to the manufactured solution
u =

r2, if 0 ≤ r2 < 1,
α(r2)− (α− 1), if 1 ≤ r2.
The test problem is performed on the square domain Ω = [−2, 2]2 with an interior circle
of radius 1. The mesh is separated into two sub-divisions, inside and outside of this circle,
and mesh nodes are placed on the boundary of this circle to better catch the jump.
We may examine the effects of a jump in the diffusion coefficient by changing the mag-
nitude of α. If α = 1 then there is no jump of the diffusion coefficient, and we would expect
second-order spatial convergence as the mesh is refined. The purpose of this test is to inves-
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Figure 5.9. Two-dimensional mesh for discontinuous diffusion coefficient test using N = 266
spatial nodes.
tigate whether second-order convergence will deteriorate as α is decreased and the jump in
diffusion coefficient grows.
Since we use a 2D mesh in which N is proportional to h, we use 1/
√
N to estimate h.
Convergence results for this test with values of α ∈ {1, 0.5, 0.1, 0.05, 0.01} are provided in
Table 5.2. Here, we give the L2 error as the mesh size increases using uniform refinement
of the triangular mesh. From these results, we observe the expected quadratic convergence
with α = 1. Furthermore, even as the jump in diffusion coefficient grows to a factor of 100,
we retain quadratic convergence of the method. We note that a key requirement we found in
this test was that the mesh needed to be refined to match the geometry of the circular region;
if instead we merely refined the original triangular mesh, the convergence rate deteriorated
to 1.
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Table 5.2. Convergence results for diffusion equation with discontinuous diffusion coefficient.
N
α
1.0 0.5 0.1 0.05 0.01
266 2.01e-1 1.04e-1 2.91e-2 2.15e-2 1.70e-2
946 5.22e-2 2.70e-2 7.49e-3 5.50e-3 4.35e-3
3635 1.30e-2 6.73e-3 1.88e-3 1.38e-3 1.09e-3
14409 3.27e-3 1.69e-3 4.75e-4 3.46e-4 2.73e-4
57377 8.19e-4 4.23e-4 1.18e-4 8.66e-5 6.84e-5
conv. rate 2.05 2.05 2.05 2.05 2.05
5.5. ODE analysis of the chemical reaction network
We now examine our model for the reaction network in the region Ω1, to study its
ability to capture the correct interactions between virus, medication, chemoattractant, and



































= −kTV T − dTT + gT , (5.4e)
with continuous diffusion coefficients, spatially-constant initial conditions, and homogeneous
Neumann boundary conditions. Thus since there is no flux through the boundary, and all
spatial gradients are initially zero, the only ‘active’ terms in the model are those corre-
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sponding to reactions within and between components. All of the tests in this section are
performed on the relatively coarse two-dimensional mesh shown in Figure 5.10.
Figure 5.10. Square mesh for reaction network tests.
5.5.1. No medicine stage
We first test the chemical reaction network without medication and an initially small




























= −kTV T − dTT + gT , (5.5d)
For the implementation, we use:
 time span (days) [0, tF ] = [0, 25],
 constant diffusion coefficients DV = Dc = DI = DT = 1,
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 reaction parameters fT = 1.0, kT = 0.8, pc = 0.1, and iT = 1.1,
 particle growth/clearance rates rI = 20, dV = 23, λ = 0.5, δ = 0.39, and dT = 0.01,
 chemotaxis parameter χ = 0, and T-cell source gT = 2,
 spatially-constant initial conditions V0 = 2, c0 = 1, I0 = 1, and T0 = 2.
Figure 5.11. Average concentration of virus, chemoattractant, infected and healthy T-cells
as functions of time for the ‘no medicine’ reaction test (Section 5.5.1).
Results from this test are shown in Figure 5.11, where we plot the time history of the
spatially-averaged quantities of each variable. Here, we can see a rapid increase of virus load
and then the decrease of viral load caused due to the expected immune response. Also, we
see the decrease of healthy T-cells caused by infection and immune response. We note that
here the overall quantity in T-cells does not eventually succumb, due to the generation term
gT . As in [21, 53, 59], this infection progress based on our model resembles the actual viral
infection progression with the damped oscillations.
5.5.2. Initial HIV treatment stage
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We now test our ODE reaction network with an initially high virus load, but now in the
presence of medicine, which corresponds to the phase where a patient is undergoing HIV
treatment. Hence we use model 5.4 with:
 time span (days) [0, tF ] = [0, 25],
 constant diffusion coefficients DV = DM = Dc = DI = DT = 1,
 reaction parameters fT = 1.0, eM = 0.5, kT = 0.8, pc = 0.1, and iT = 1.1,
 particle growth/clearance rates rI = 20, dV = 23, dM = 0.3, λ = 0.5, δ = 0.39, and
dT = 0.01,
 chemotaxis parameter χ = 0, medicine source hM = 4, T-cell source gT = 1,
 spatially-constant initial conditions V1 = 5, M1 = 5, c1 = 0.5, I1 = 1, and T1 = 2.
We highlight two of these parameters in particular. Since as the infection progresses the
patient keeps losing CD4 T-cells, we have reduced the T-cells generation rate to gT = 1.
Moreover, since the patient takes medicine daily in this stage, we add the medicine source,
hM = 4.
Figure 5.12. Average concentration of virus, medicine, chemoattractant, infected and healthy
T-cells as functions of time for the ‘Initial HIV treatment’ reaction test (Section 5.5.2).
72
Results from this test, where we again plot the time history of the average values for
each variable, are shown in Figure 5.12. We note two key items in this Figure. First, the
concentration of virus decreases to near-zero levels as treatment proceeds. Second, we see
a notable decrease in the concentration of infected T-cells. Both of these effects accurately
model the course of HIV under appropriate treatment.
5.5.3. End of HIV treatment stage
We finally test what happens in our chemical reaction network when HIV treatment
ends. Even though the concentration of virus is essentially zero, the presence of a reservoir
of infected T-cells in the body should cause the virus to rebound after medication is halted.
For this test, we return to the model 5.5, this time using the parameters:
 time span (days) [0, tF ] = [0, 25],
 constant diffusion coefficients DV = Dc = DI = DT = 1,
 reaction parameters fT = 1.0, kT = 0.8, pc = 0.1, and iT = 1.1,
 particle growth/clearance rates rI = 20, dV = 23, λ = 0.5, δ = 0.39, and dT = 0.01,
 chemotaxis parameter χ = 0, and T-cell source gT = 2,
 spatially-constant initial conditions V2 = 0, c2 = 0.5, I2 = 0.1, and T2 = 2.
We again point out a few key parameters for this test. To model an ‘undetectable’ virus load
in the body, we begin with an initial virus concentration V2 = 0. Moreover, with this lack of
HIV in the body, we anticipate that the T-cell growth rate may return to normal (gT = 2).
Lastly, to model the reservoir of infected T-cells, we begin with a very small concentration
of infected cells, I2 = 0.1.
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Figure 5.13. Average concentration of virus, chemoattractant, infected and healthy T-cells
as functions of time for the ‘End of HIV treatment’ reaction test (Section 5.5.3).
Figure 5.13 shows the results from this test. As expected, w see a quick rebound of
both the virus and infected T-cell concentrations, along with the corresponding decrease
in concentration of healthy T-cells, even with only the very small initial concentration of
infected cells.
Based on this suite of chemical reaction network tests, we conclude that these terms and
corresponding parameters in our chemical reaction network are able to correctly model the




In this Chapter, we will analyze our model biologically. Instead of measuring convergence
and scalability using manufactured solutions and idealized parameters, we will use the phys-
ical parameters from Table 2.1.2 and compare model predictions against the clinical course
of HIV infection.
For each of these investigations we tested with both the backward Euler ODE solver
and ARKODE solver; the results shown here are produced using the implicit ARKODE
solvers with the relative tolerance to be 10−6 and the absolute tolerance to 10−8. For the
choice of preconditioner, we tested with both the block diagonal preconditioner and the
lower triangular preconditioner. These results utilize the block diagonal preconditioner as it
is simple, efficient, and proved to be very effective for the wide range of tests in this chapter.
And all these tests are produced with 16 MPI tasks.
6.1. Infection in the absence of medication
As with our reaction network test in Section 5.5.1, at the beginning of infection, the
patient may not know about the virus and will not use medicine. Thus in this stage, there





























= −kTV T − dTT + gT . (6.1d)
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We now perform the test on the two-dimensional domain with unstructured triangular grid
shown in Figure 6.1,
Figure 6.1. Coarse (N=943) two-dimensional lymph domain Ω1 used for testing the model
(6.1).
We use the refinement mesh which is constructed in Gmsh when we perform the test in
the following subsections. Now, we use the biological parameters
 Dvout = 1.0, Dvin = 0.1
 Dc = 0.8
 DIout = DTout = 0.1, DIin = DTin = 0.01,
 fT = 1.0, rI = 20, dV = 23,
 λ = 0.5, pc = 0.1,
 iT = 1.1, δ = 0.39,
 χ = 1, kT = 0.8, dT = 0.01, and gT = 2.
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At the beginning of infection, the virus load is low, so we set the initial condition of virus
to be V0 = 2 [53]. At this point we assume that the immune system has just recognized the
infection, producing the chemoattractant c to request more T-cells as part of the adaptive
immune response. Thus we set the initial conditions c0 = 1.0 and T0 = 2 [9]. Also, consider-
ing the infection rate of T-cells, we set the initial condition of infected T-cells to be I0 = 1.
The existence of chemoattractant c is local to the lymph node, so we use homogeneous Neu-
mann boundary conditions. We also apply homogeneous Neumann boundary conditions for
the virus, infected and healthy T-cells because of the low lymphatic circulation rate. We
test this period with 25 days, so the time span is [t0, t1] = [0, 25].
As we metioned in Chapter 2, CD4 T lymphocytes are a target of HIV, and loss of T-
cells will ultimately lead to AIDS. While in the earliest stages of HIV infection, there is still
a difference between the number of peripheral T-cells actually infected and the spreading
paralysis of CD4 T-cell function. Homoeostasis is maintained in the early stage of infection,
since the increase of CD8 T-cells balances the loss of CD4 T-cells. However, infection of
HIV will kill plenty of memory T-cells and lead to an increase in naive T-cells to keep
homoeostasis, approximately 80 times above the concentration in normal adults. There is a
theory called “tap and drain” to describe this balance between CD4 and CD8 T-cells caused
by HIV infection [54]. In Figure 6.2, we can see this balance intuitively.
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Figure 6.2. “Tap and drain” model describes the balance of CD4 and CD8 T-cells caused
by HIV infection [54].
Figure 6.3. Average concentration of virus, chemoattractant, infected cells and healthy T-
cells throughout Ω1 as functions of time for the “Infection in the absence of medication” test
from Section 6.1.
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In Figure 6.3 we plot the average concentration of each species (virus, T-cells and infected
cells) throughout the domain as functions of time. From this figure, we can see that the model
correctly reproduces the clinical course of HIV infection – we see an initially rapid increase,
followed by a decrease in viral load, corresponding with an eventual loss of healthy immune
cells by the end of the 25-day time period.
6.2. Effects of medication on HIV infection
Similar to our test with the idealized reaction network including medicine from Section
5.5.2, after the patient has become aware of the infection, antiretroviral medication would
be supplied. Hence, we can use the full model to do the analysis. As derived in Chapter 2,



































= −kTV T − dTT + gT . (6.2e)
with biological parameters
 Dvout = 1.0, Dvin = 0.1
 Dc = 0.8
 DM = 2
 DIout = DTout = 0.1, DIin = DTin = 0.01,
 fT = 1.0, rI = 20, dV = 23,
 eM = 0.5, dM = 0.3,
 λ = 0.5, pc = 0.1,
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 iT = 1.1, δ = 0.39,
 χ = 1, kT = 0.8, dT = 0.01, and gT = 2.
For this stage, we set these initial conditions from the final average solutions of the previ-
ous test, i.e., V1 = 0.59, M1 = 5.0, c1 = 0.05, I1 = 0.69, T1 = 0.41. for the chemoattractant
c. However, we now apply nonhomogeneous Neumann boundary conditions for V , M , I
and T . Specifically, antiretroviral medication is typically administered orally, and it must
enter the lymph node though the boundary as a constant source, so we use ∇M · n = 5.0
at ∂Ω1. Similarly, the virus, lymphocytes and infected cell particles enter the lymph node
though its boundary as the infection develops, so we set ∇V · n = 0.15, ∇I · n = 0.1, and
∇T · n = 3.0 on the boundary ∂Ω1. We perform this test using a 25 day period, so the time
span is [t1, t2] = [25, 50].
Following our discussion of working mechanisms for antiretroviral drugs in Chapter 2, the
antiretroviral drugs take effect by diminishing the virus’s ability to infect susceptible cells
through reducing the infection rate fT , i.e., fTM =
fT
1+ΦM
, or diminishing virus replication by




this section, we explore the effects of different medication combinations on the HIV infection
by modifying these parameters Φ and Ψ.
6.2.1. Φ = 1 and Ψ = 1
We first test the case where both types of antiretroviral medication are administered.
Since there should be spatial variation in the distribution of species inside Ω1 due to the
nonhomogeneous boundary conditions, we separately plot time histories of the spatially-
averaged concentrations of each species in Figure 6.4, followed by plots in Figure 6.5 of the
spatial distribution of virus, medicine, chemoattractant, infected cells and healthy T-cells at
time t = 50.
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Figure 6.4. Average concentration of virus, medicine, chemoattractant, infected cells and
healthy T-cells throughout Ω1 as functions of time, using the medication parameters with
Φ = Ψ = 1 from Section 6.2.1.
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Figure 6.5. Distribution of virus (upper left), medicine (upper right), chemoattractant (mid-
dle left), infected cells (middle right) and healthy T-cells (bottom) throughout Ω1 at the time
t = 50, using the medication parameters with Φ = Ψ = 1 from Section 6.2.1.
Here we can see the decrease in viral load with the supply of medicine, espacially inside
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of B-cell zone. However, the concentration of infected cells remains relatively high, since
neither medicine nor healthy T-cells kill the infected cells directly. This may explain why
most patients must take antiretroviral drugs indefinitely, and we cannot currently cure HIV
infection entirely.
6.2.2. Φ = 0.5 and Ψ = 1
We now test the case where both types of antiretroviral medication are administered
but a larger quantity of Ψ is present, corresponding to medication that reduces the virus
replication rate, but only partially inhibits the virus’s ability to infect susceptible cells. We
again plot time histories of the spatially-averaged concentrations of each species in Figure 6.6,
followed by plots in Figure 6.7 of the spatial distribution of virus, medicine, chemoattractant,
infected cells and healthy T-cells at time t = 50.
Figure 6.6. Average concentration of virus, medicine, chemoattractant, infected cells and
healthy T-cells throughout Ω1 as functions of time, using the medication parameters with
Φ = 0.5 and Ψ = 1 (from Section 6.2.2).
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Figure 6.7. Distribution of virus (upper left), medicine (upper right), chemoattractant (mid-
dle left), infected cells (middle right) and healthy T-cells (bottom) throughout Ω1 at the time
t = 50, using the medication parameters with Φ = 0.5 and Ψ = 1 (from Section 6.2.2).
Here we obtain a similar result with as in Section 6.2.1 with Φ = Ψ = 1. The only
notable difference between this test and the one previous is that here, the density of virus
and infected T-cells are slightly higher.
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6.2.3. Φ = 1 and Ψ = 0.5
We now test the case where both types of antiretroviral medication are administered
but a larger quantity of Φ is present, corresponding to medication that inhibits the virus’s
ability to infect susceptible cells, but only partially reduces the virus replication rate. We
plot time histories of the spatially-averaged concentrations of each species in Figure 6.8,
and the spatial distribution of virus, medicine, chemoattractant, infected cells and healthy
T-cells at time t = 50 in Figure 6.9.
Figure 6.8. Average concentration of virus, medicine, chemoattractant, infected cells and
healthy T-cells throughout Ω1 as functions of time, using the medication parameters with
Φ = 1 and Ψ = 0.5 (see Section 6.2.3).
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Figure 6.9. Distribution of virus (upper left), medicine (upper right), chemoattractant (mid-
dle left), infected cells (middle right) and healthy T-cells (bottom) throughout Ω1 at the time
t = 50, using the medication parameters with Φ = 1 and Ψ = 0.5 (see Section 6.2.3).
In this scenario, we also observe the decrease in viral load with this combination of
medications, along with the relatively high final concentration of infected cells. All species
have higher density at the boundary because of inside flow. We note, that here the density
of virus and infected T-cells are higher than the previous two scenarios, thus we conclude
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that the full dosage of both Φ = 1 and Ψ = 1 works best.
6.3. The lymph node as an HIV reservoir
At the final stage, we’d like to test the reservoir effects of the lymph node. The virus
load in the blood will be undetectable after a period of therapy. At this point if the patient
is removed from therapy, the infection can rebound. It has been hypothesized that lymph
nodes may act as reservoirs of virus due to the slower time scales for fluid flow in these
organs. To test this we initialize the model with zero virus level, V2 = 0, low concentration
of infected cells, I2 = 0.2, zero concentration of medicine, M2 = 0, low concentration of
chemoattractant c2 = 0.05, and a relatively high level of healthy T-cells, T2 = 2.5, which we
can see from the previous medicine test. We again use the model 6.1 on the two-dimensional
domain 6.1 with the biological parameters:
 Dvout = 1.0, Dvin = 0.1
 Dc = 0.8
 DIout = DTout = 0.1, DIin = DTin = 0.01,
 fT = 1.0, rI = 20, dV = 23,
 λ = 0.5, pc = 0.1,
 iT = 1.1, δ = 0.39,
 χ = 1, kT = 0.8, dT = 0.01, and gT = 2,
To test the reservoir effect, we apply homogeneous Neumann boundary conditions so that
there is no outside influence, and we use the time period [t0, t1] = [50, 75] day.
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Figure 6.10. Average concentration of virus, chemoattractant, infected cells and healthy
T-cells throughout Ω1 as functions of time, testing the reinfection of HIV when medication
is discontinued (Section 6.3).
In Figure 6.10 we plot the average concentration of each species throughout the domain
as a function of time for this test. Here, we can see the similar infection process as shown in
Figure 6.3 for initial infection of HIV – an initially low virus load or low infected concentration
will lead to a rapid rebound of HIV virus. The low lymphatic circulation rate, along with




Discussion and Future Work
There have been several different phases of the development of antiretroviral therapy in
the history of HIV. In the early years from 1987-1990, monotherapy brought great hope as
well as depression, due to the ineffectiveness of Zidovudine or the nucleoside analogs zal-
citabine, didanosine and stavudine. Then in September 1997, it was found that combination
therapy with two nucleoside analogs was more effective than monotherapy.
It has been forty years since AIDS was first detected. With the advent of anti-HIV
drugs developed in the 90’s, HIV has been changed to a chronic disease from a terminal one.
However, it has still not been completely eradicated. By modeling the concentration of the
ART drugs (medicine) entering and passing through a lymph node, we wish to learn more
about the biology process of HIV infection and the corresponding immune response, as well
as whether the slower circulation rate within the lymph nodes renders them as potential HIV
reservoirs.
This thesis discusses our construction and solution of a mathematical model to perform
these analyses. In Chapter 1, we briefly introduced the history of HIV, and discussed some
hypotheses about the difficulty in finding an ultimate cure for AIDS.
In Chapter 2, we discussed some of the basic biology related to this thesis. We introduced
the anatomy of human lymph nodes and their functionality, notably how these organs play
a key role in lymph circulation and immune response. T lymphocytes are responsible for the
cell-mediated immune responses of adaptive immunity, and HIV is a retrovirus which attacks
the immune system and leads to loss of immune control. Also, we introduced the concept
of latently-infected cells, which is is a group of infected T-cells that are not yet actively
producing HIV, and that represent long-living cellular reservoirs for HIV. With all these
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biological concepts, we then focused on constructing a mathematical model of the lymph
node.
Most of the previous mathematical models of these processes treat the lymph node as
a homogeneous vessel, ignoring its complex architecture. In our framework, we instead
construct a more realistic 3D lymph node model to study the more realistic spatio-temporal
dynamics of virus, immune cells and medicine.
We presented results from previous work and found three types of models that we lever-
aged within our model. Bocharov and collaborators [12] proposed a reaction-diffusion PDE
model that realized the importance of lymphatic structure for understanding particle dynam-
ics in lymph nodes. Dunia and collaborators [21] focused on the reaction network responsible
for HIV infection, introducing models with the flexibility to consider the significant variety
of infection cases step by step, including some ideas about the usage of medicine throughout
the clinical course of infection. Finally, we introduced the classical Keller-Segel model of
chemotaxis, which is used to model the immune response of T-cells to a localized infection.
Building off of this previous work, we construct a mathematical model consisting of
the following variables: virus (V ), medicine (M), chemoattractant (c), infected cells (I),
and healthy T-cells (T ). We consider the anatomy of the lymph node as consisting of two
parts, an inner part Ω1 which we model by an advection-reaction-diffusion system of partial
differential equations, and an outer part Ω2 where we utilize a modified diffusion-reaction
model combined with the Navier-Stokes equations.
Then in Chapter 3, we presented the numerical methods we use to approximate solu-
tions to the model (2.2) for the region Ω1. We used the finite element method to discretize
the spatial domain, and constructed the corresponding nonlinear system of ODEs. For the
time integration, we described approaches based on Backward Euler, singly diagonal implicit
Runge-Kutta (SDIRK) and Backward Differentiation formula (BDF). We solved the corre-
sponding systems of implicit algebraic equations using Newton’s method. We approximated
the lymph node geometry using an unstructured tetrahedral 3D mesh produced using the
Gmsh package. We finally implemented the resulting mathematical model using the MFEM
90
finite-element infrastructure.
In Chapter 4, we presented a detailed discussion of the preconditioner we used for the
Jacobian system. We constructed four different types of block preconditioners: block diago-
nal, lower triangular, and two approximate Schur complements. Then we presented related
work suggesting that our preconditioners should be scalable. We also presented numerical
tests in Matlab to predict the scalability numerically. Afterwards, we applied these four
types of preconditioners to a steady-state version of our model and found that the number
of iterations of the preconditioned GMRES solver remained relatively constant (for each
preconditioning approach), numerically verifying the algorithmic scalability of our solution
approach.
In Chapter 5, we performed four different types of tests to verify our computational
implementation before solving the target biological model. In section one, we discussed the
structure of the lymph node and constructed its 2D and 3D mesh. Since the lymph node
is composed of almost identical regions called nodules, we constructed a discretization of
one nodule for our spatial model. Then in section two, we did a small test to verify the
chemotaxis phenomenon using the classical Keller-Segel model and modified corresponding
term extracted from our model. In section three, we checked the convergence of our model
on a steady-state version of our model with a manufactured solution. In section four, we
tested the influence of the discontinuous diffusion coefficient.
Finally, in Chapter 6, we analyzed our model biologically. We used biological parameters
and compared our model predictions with the clinical course of HIV infection. First, the
patient did not know about the infection, thus we modeled the initial phase of the infection
without any medicine supplied. We computed the model with virus (V ), chemoattractant
(c), infected cells (I) and healthy T-cells (T ) which showed the growth in both the viral load
and infected cell concentrations, along with the corresponding decrease in healthy T-cell
concentration. Then we supplied the medicine to the patient. Since different medications
work using different mechanisms, we tested different combinations of medicines. Finally, to
test the ‘reservoir’ hypothesis from Chapter 1, we performed tests that examined the effects
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of spatial inhomogeneity on viral dynamics.
In the future, we will continue these efforts to include the model in the sinus region Ω2,
coupling it with the model in region Ω1. This coupling of the two models will proceed in
multiple different stages.
 Spatially couple the model for different interfaces. We just construct one nodule right
now. We need to couple several nodules together to get the whole lymph node.
 Couple the model in the different time scale. The model in region Ω1 is an advection-
diffusion-reaction model while there is a transport model in region Ω2. The fluid
transports in different way and with a faster time scale.
Based on the complexity of the problem, to properly handle this multi-domain, multi-physics,
multi-rate PDEs system it will require more robust and flexible numerical methods.
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